

**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF RHODE ISLAND**

STATE OF COLORADO, *et al.*

Plaintiffs,

v.

U.S. DEPARTMENT OF HEALTH AND HUMAN
SERVICES, *et al.*

Defendants.

Case No.

**DECLARATION OF
JOHANNE MORNE**

DECLARATION OF JOHANNE MORNE

I, Johanne Morne, hereby declare:

1. I am Johanne Morne and I am the Executive Deputy Commissioner at the New York State Department of Health (“Department”).
2. The facts set forth herein are based upon my personal knowledge, conversations with relevant staff, and/or a review of the files in the Department’s possession.
3. As a part of my work for the Department, I have knowledge of many of the grants and cooperative agreements awarded to the Department, and those that are awarded to and administered by Health Research, Inc. (“HRI”) on behalf of the Department under the New York State Finance Law, including those from the Centers for Disease Control and Prevention (“CDC”) and the National Institutes of Health (“NIH”) to perform lifesaving work and research.
4. HRI applies for, is awarded, and administers select grant awards and cooperative agreements on behalf of the Department, under the New York State Finance Law, and as a result, HRI is listed as the “Recipient,” of the Notice of Award (“NOA”).
5. On March 25, 2025, and March 26, 2025, the Department and HRI received notice, with effective dates of March 24, 2025, that any remaining funding from various CDC and NIH grants were being terminated retroactively. To date, this includes:
 - a. Epidemiology and Laboratory Capacity (“ELC”) for Prevention and Control of Emerging Infectious Diseases in New York State; ELC Enhancing Detection and ELC Enhancing Detection Expansion (collectively, the “Supplemental ELC Grant”);

- b. National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved, Including Racial and Ethnic Minority Populations and Rural Communities (“Health Disparities Grant”); and
- c. Immunization COVID-19 Supplemental Funding (“COVID-19 Supplemental Funding Grant”).

6. The grant awards detailed above (collectively, the “Grant Awards”) provided the Department with funding streams to assist with various COVID-19 and post-pandemic response efforts and critical public health functions, including testing, surveillance, monitoring and reporting, amongst other approved infectious disease activities within the intended scope of the Grant Awards. As the impacts of the pandemic and the needs of communities across the State evolved, the Grant Awards continued to be used, consistent with instructions and approved activities regarding allowable funding activities, directly benefitting COVID-19 related public health activities or responding to fundamental infrastructural needs and gaps identified and developed as part of the COVID-19 response and addressing other approved infectious diseases activities within the intended scope of the Grant Awards.

7. The pandemic exposed many gaps in existing public health infrastructure that began to be improved during the pandemic through the use of Grant Awards funding and are still being improved, maintained, and monitored. For example, the funding may support testing for COVID-19 alone or as a part of a multi-pathogen panel; surveillance of COVID-19 within infrastructure that also integrates surveillance of other infectious diseases; systems that manage COVID-19 and other infectious disease outbreaks; immunization registry improvements, which include the COVID-19 vaccine; strengthening the capacity of organizations across the state that work on projects improving their local communities’ overall health and wellness; and

improvement and maintenance of infection control standards that would be expected to have a positive impact on preventing outbreaks, and other approved infectious disease activities within the intended scope of the awards.

8. The termination of the Grant Awards is already causing devastating, far-reaching consequences – including the need for unexpected layoffs of dedicated public health personnel responsible for managing and conducting critical public health work functions across the state. The Grant Awards terminations impact local communities throughout New York State, which have directly benefited from the funding of the Grant Awards, and will impact collaborative work with local vendors, subcontractors, and county health departments, within the intended scope of the Grant Awards.

Supplemental ELC Grant

9. The Epidemiology and Laboratory Capacity Cooperative Agreement (“ELC Base”) has been in existence since 1995. It provides critical support for New York State, territorial, and certain large city health departments for public health activities related to infectious disease. According to the CDC, which provides the ELC funding, the “[ELC] program provides flexible funding to the nation’s health departments to detect, prevent and respond to infectious disease outbreaks [and]...administers the [ELC] Cooperative Agreement, a funding mechanism that awards critical support for infectious disease programs and projects.”¹ Funding is provided in five-year cycles with annual renewals. In 2024, the total funding awarded for all health departments was approximately \$364 million dollars; for the current budget period of August 1, 2024, through July 31, 2025 approximately \$20.5 million was

¹ See CDC; Epidemiology and Laboratory Capacity; *The Epidemiology and Laboratory Capacity (ELC) Program | Epidemiology and Laboratory Capacity | CDC*, available at <https://www.cdc.gov/epidemiology-laboratory-capacity/php/about/index.html> (last viewed March 28, 2025).

awarded to the New York State Health Department. Funding supports personnel and provides other vital resources for activities such as general surveillance, outbreak response, health information systems, wastewater surveillance, foodborne disease surveillance and investigation, healthcare-associated infections, antibiotic resistance, viral respiratory disease surveillance and response, vector-borne disease, fungal disease, and maternal infections that can affect infants. Additionally, funding supports a wide range of laboratory work related to the above activities, such as advanced molecular detection, bacteriology, mycology, and virology. Supplemental awards are sometimes distributed in response to emergencies such as the Mpox, Zika and Ebola virus outbreaks. Much of the supplemental COVID-19 funding the CDC distributed during the COVID-19 pandemic was awarded using the ELC mechanism.

10. On April 23, 2020, the first NOA for the Supplemental ELC Grant awarded through the ELC Base (Grant No. 6 NU50CK000516-01-06) was received by the Department, awarding supplemental funding for the budget period of August 1, 2019, through July 31, 2020, for COVID-19 response efforts. A copy of that NOA is attached hereto, as **Exhibit A**. The second NOA for the Supplemental ELC Grant was awarded on January 14, 2021. This award was incorporated into and supplemented the existing five-year ELC Base already awarded and administered by HRI on behalf of the Department through HRI for the project period of August 1, 2019 through July 31, 2024, which was awarded to provide base funding specific to epidemiology, laboratory, and health information system-related efforts of the Department. The NOA for year one of the original project period of the base ELC Base for the five-year period dated August 1, 2019, through July 31, 2024, is attached hereto as **Exhibit B**. (1 NU50CK000516-01-00).

11. The awarded April 23, 2020 NOA, administered on behalf of the Department provided supplemental funding of \$18,544,755. As with most awards, the budget period for the April 23, 2020 NOA for the Supplemental ELC Grant was one year.

12. The Supplemental ELC Grant was awarded as follows:

- a. \$700,248,982 known as ELC Enhancing Detection (BP 1), for the budget period of August 1, 2019, through July 31, 2020, (6 NU50CK000516-01-07), issued on May 18, 2020. A copy of that NOA is attached hereto as **Exhibit C**.
- b. \$639,861,809 known as Enhancing Detection Expansion (BP2) for the budget period of August 1, 2020, through July 31, 2021, (6 NU50CK000516-02-05), issued on January 14, 2021. A copy of that NOA is attached hereto, as **Exhibit D**.

13. The Supplemental ELC Grant NOAs contained the following language:

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b)).

14. Drawdowns from the Supplemental ELC Grant typically occur on a weekly basis on expenses paid prior to the drawdowns.

15. Since the initial award, the Supplemental ELC Grant funds have been used in a manner fully consistent for approved activities within the intended scope of the awards.

16. On Tuesday, March 25, 2025, HRI received a notification, without any prior notice or indication, that the ELC Base and supplements, including the Supplemental ELC Grants, were terminated effective retroactively to March 24, 2025 (“March 24, 2025 Termination Notice”). A copy of the March 24, 2025 Termination Notice is attached hereto, as **Exhibit E**.

17. The March 24, 2025 Termination Notice stated that the purpose “is to terminate the use of any remaining COVID-19 funding associated with this award. The termination of this funding is for cause.” It further states that “[t]he end of the pandemic provides cause to terminate COVID-related grants and cooperative agreements [which] were issued for a limited purpose: to ameliorate the effects of the pandemic.” It stated that “[n]ow that the pandemic is over, the grants and cooperative agreements are no longer necessary as their limited purpose has run out.” *Id.*

18. Realizing it had erroneously terminated the entire ELC Base and all supplements rather than just the Supplemental ELC Grant with supplemental COVID-19 funding, on March 25, 2025, at approximately 1:23 p.m., an updated message was sent by the CDC, stating “On [sic] yesterday, March 24, 2025, the CDC issued Notices of Award to terminate certain COVID-19 funding, as directed. During that process, the Budget Period and Period of Performance dates were inadvertently changed to March 24, 2025, for the entire award. This was done in error and will be corrected by COB today. Thank[sic] you, Office[sic] of Grant Services.” *See Exhibit F.*

19. The Supplemental ELC Grant was not originally supposed to terminate until the project end date of July 31, 2026. A copy of the October 17, 2023, NOA awarding a no-cost extension of the project period is attached hereto as **Exhibit G**. At the time of termination, approximately \$235 million was left unspent from the Supplemental ELC Grant.

20. The March 24, 2025, Termination Notice also stated that “[n]o additional activities can be conducted, and no additional costs can be incurred.” Additionally, only thirty (30) days from the March 24, 2025, Termination Notice was permitted to submit final Federal Financial Reports (“FFR’s”) for impacted document numbers with funds authorized and expended for the report timeframe and balance of unobligated funds. *See Exhibit E.*

21. Prior to the grant award termination, the CDC had never provided notice, written or otherwise, that the grant administration had been in any way unsatisfactory. HRI prides itself on meeting grant requirements and maintaining high performance standards. This is certainly the first termination notice of its kind received by HRI, which is not otherwise aware at this time of any HRI award being terminated for cause related to a violation or lack of performance.

22. To the contrary, as recently as February 7, 2024, the Department was notified of a CDC update related to using these funds, posted as an announcement in the CDC's Cooperative Agreement Management Platform ("CAMP"), a system used by the Department and the CDC to input grant-related information and workplans. This announcement, entitled Updated Companion Clarifying Document for ELC Enhancing Detection ("ED") and Enhancing Detection Expansion ("EDE") COVID-19 Funding, dated January 31, 2024, clarified allowable activities for the funds ("January 31st CDC Announcement"). The January 31st CDC Announcement contained no indication that the grant funding was going to be halted due to the end of the federal Public Health Emergency, or that the funds could not be used to support post-pandemic response. Conversely, it stated that:

*[a]s SARS-CoV-2/COVID-19 testing, surveillance, monitoring, and reporting becomes more integrated into the routine activities for respiratory pathogens more broadly, COVID-19 funded activities should still focus on directly benefiting COVID-19-related public health activities and improved situational awareness that may inform public health action. COVID-19 funded infrastructure, and activities may integrate other pathogens and syndromes, in addition to SARS-CoV-2 and COVID-19, as long as detection/assessment/reporting/visualization activities for SARS-CoV-2 and COVID-19 are included in their routine scope of work. Activities can be conducted and integrated within **broader respiratory pathogen program activities**.*

See January 31st CDC Announcement attached hereto as **Exhibit H**.

23. The Department relied and acted upon its expectation and understanding that the CDC would fulfill its commitment to provide the Supplemental ELC Grant funding it had already awarded.

24. While the impacts of the immediate termination of the Supplemental ELC Grant are still being fully evaluated, the consequences are unequivocally devastating to New York's post-pandemic efforts to manage public health, build and rebuild our public health infrastructure, and prepare for future public health emergencies measures implemented as part of the COVID-19 response. These impacts will be long-lasting, cutting across all communities - geographically and demographically - and will be deeply felt by all New Yorkers for generations to come. Losing this funding will shutter multiple areas of work that are foundational components of the Department's response to COVID-19 and other pathogens of significant threat to the public. The loss of this critical funding will undermine both the progress we have made in preparing for future pandemics or infectious disease outbreaks and the lessons learned from our most recent pandemic response.

25. These cuts weakened the backbone of our New York State public health infrastructure by significantly reducing—and in some cases eliminating—the resources that support infection prevention and infection control work, surveillance and symptom reporting systems, laboratory support and testing, data collection and analysis, public facing dashboards, and data and analytics systems, with no advance notice to prepare.

26. Specifically, the loss of funds from the Supplemental ELC grant will adversely impact or eliminate the following:

- a. Collecting valuable health care facility data, known as the New York State Health Electronic Response Data System (“HERDS”), needed to

monitor various health care providers' (hospitals, providers, nursing homes, adult care, and home care) bed capacity to ensure people's ability to access care and for the Department to prepare and respond to health emergencies;

b. Ability to describe disease incidence and prevalence using epidemiologic data analysis, data quality assurance, and data interpretation work for respiratory disease such as COVID-19 and a wide variety of other illnesses; Data operations and enhancements for the Department's core systems used daily to safeguard against infectious diseases: case reporting, emergency department syndromic surveillance, outbreak management of health care-associated infections, and electronic symptom self-monitoring and electronic case reporting systems;

c. Ability to operate the Department's 24/7 Surge Operations Center that assists hospitals when they do not have ample bed capacity or ability to provide a specialized type of care, as well as to provide vital emergency preparedness and response to swiftly react and respond to crises across the state;

d. Operational support for the maintenance of the New York State Immunization Information System ("NYSIIS"), used daily by providers and schools every day to ensure children are vaccinated against contagious diseases;

e. The Department's COVID-19 and other infectious disease dashboards for rapid public access to collated, interactive data;

f. Contracts to enhance informatics infrastructure such as the New York State Health Commerce System ("HCS"), widely used by multiple programs across the Department, hospital facilities for the purposes of data review and

reporting of adverse event, and local counties, the New York State Electronic Death Registry System (“EDRS”), which is used to record deaths by physicians and funeral homes, as well as communicable disease surveillance, lab reporting and testing systems;

g. Ability to provide guidance and assistance for local health departments in outbreak surveillance, reporting, and investigations;

h. Infection preventionists and epidemiologists to assist health care facilities with outbreak investigations and improve infection control, resulting in impaired health and safety protection of our most vulnerable residents living in nursing homes, a population that is at high risk for negative consequences from COVID-19;

i. Contracts to upgrade and strengthen the data and technology infrastructure that supports the Department’s Wadsworth Center’s public health Laboratory Information Management System, which is a system we are required by regulation, 42 C.F.R § 493 *et Seq.* to have in place to maintain to receive and track specimens, report test results, and has also been used to house information on testing and surveillance of infectious diseases;

j. Disintegration of an established genomic sequencing consortium that provides statewide capacity to rapidly and extensively respond to outbreaks and surveillance needs, identifying circulating SARS-CoV-2 variants, tracking pathogen evolution, and other infectious agents such as the measles, polio, Zika and Mpox viruses, and agents of bioterrorism;

k. Courier contract for the transport of specimens to the laboratories of the Department's Wadsworth Center, from patients with suspected high consequence pathogen infections posing serious and immediate public health threat;

l. Ability for the Department's Wadsworth Center to provide rapid genomic surveillance data for SARS-CoV-2 in wastewater and clinical specimens as well as other emerging pathogens such as the H5N1 influenza, polio, and measles viruses;

m. Contract to modernize the Department's Vital Records system, which is key to confirming and tracking COVID-19 related deaths, as the pandemic revealed an infrastructure gap and a need to update Vital Records systems to allow for more rapid response;

n. Public awareness and media campaigns focused on combating vaccine misinformation and disinformation on viruses;

o. The public health fellowship program, including program support staff and fellows at both the Department and at local health departments across New York State, who, in part, work on advancing the above initiatives as well as other public health goals of the State as related to infection control, outbreaks, and disease surveillance, amongst other efforts;

p. Day-to-day assistance of CDC Foundation² staff working closely with Department staff to maintain 24/7 health care facility surge operational needs, electronic reporting of health care facility data, and implementation of an

² The CDC Foundation is a global nonprofit, that helps the CDC and manages public health programs that impact chronic and infectious diseases and emergency threats like COVID-19.

automated data reporting system. Additionally, CDC Foundation staff work alongside of Department staff to understand the state of readiness and active infection response risk for the approximately 597 nursing homes statewide, and provide support for wastewater surveillance of infectious disease, amongst other functions; and

q. The monitoring of service contracts on laboratory equipment maintained in facilities statewide, whose certification compliance is required by state and federal regulations for diagnostic testing.

Health Disparities Grant

27. The CDC awarded grants to health departments with the goal of addressing COVID-19 related health disparities, to “advance health equity amongst populations that are at high-risk and underserved, including racial and ethnic minority groups and people living in rural areas.” Among other goals, the CDC hoped to “improve testing and contact tracing capabilities; develop innovative mitigation and prevention resources and services; improve data collection and reporting; build, leverage and expand infrastructure support; and mobilize partners and collaborators to advance health equity and address social determinants of health as they relate to COVID-19.” The CDC intended to ensure “resources are available to maintain and manage physical and mental health, including easy access to information, affordable testing, and medical and mental health care.” A copy of the CDC’s March 17, 2021, Archived Press Release is attached hereto as **Exhibit I**.

28. On May 26, 2021, the NOA for the Health Disparities Grant (Award No. 1 NH75OT000075-01-00) was received by the Department, awarding funding for the budget

period of June 1, 2021, through May 31, 2023. A copy of that NOA is attached hereto, as

Exhibit J.

29. The May 26, 2021, NOA awarded funding in the amount of \$33,726,393. *Id.*
30. The Health Disparities Grant was amended and extended thereafter as follows:
 - a. By notice dated March 17, 2023, (Award No. 1 NH75OT000075-01-01), the CDC amended the original NOA to approve a 12-month no cost extension altering the budget and project period end dates to extend to May 31, 2024, per a request submitted February 28, 2023, by the recipient. This NOA contained the following language:

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b)).

A copy of that NOA is attached hereto, as **Exhibit K.**

- b. By Notice dated March 27, 2023, (6 NH75OT000075-01-02), the CDC issued a correction to the Approved Budget allocations. A copy of that NOA is attached hereto, as **Exhibit L.**
 - c. By Notice dated February 28, 2024, (6 NH75OT000075-01-03), the CDC approved a 24 month no-cost extension, altering the budget and project period end dates, extending them from May 31, 2024, to May 31, 2026. A copy of that NOA is attached hereto, as **Exhibit M.**

31. Drawdowns from the Health Disparities Grant typically occur on a weekly basis on expenses paid prior to the drawdowns.

32. Since the initial award, the Health Disparities Grant funds have been used in a manner fully consistent with CDC's approved activities within the intended scope of award.

33. Again, HRI prides itself on meeting grant requirements and maintaining high performance standards and emphasizes that this is certainly the first termination notice of its kind received by HRI, which is not otherwise aware at this time of any HRI award being terminated for cause related to a violation or lack of performance.

34. On Tuesday, March 25, 2025, HRI received a notification, without any prior notice or indication, that the Health Disparities Grant was terminated retroactively, effective March 24, 2025, ("March 24, 2025 Termination Notice"), well in advance of the scheduled termination date of May 31, 2026, as previously guaranteed by the February 28, 2024 NOA (6 NH75OT000075-01-03). The March 24, 2025, Termination Notice is attached hereto as **Exhibit N**. At the time of termination, approximately \$11.5 million was left unspent from the Health Disparities Grant.

35. The March 24, 2025, Termination Notice stated that the purpose "is to terminate the use of any remaining COVID-19 funding associated with this award. The termination of this funding is for cause." It further states that "[t]he end of the pandemic provides cause to terminate COVID-related grants and cooperative agreements [which]] were issued for a limited purpose: to ameliorate the effects of the pandemic." It stated that "[n]ow that the pandemic is over, the grants and cooperative agreements are no longer necessary as their limited purpose has run out." *See id.*

36. Notably, the March 24, 2025, Termination Notice stated that “[n]o additional activities can be conducted, and no additional costs can be incurred.” The March 24, 2025 Termination Notice only provided a mere thirty (30) days from the March 24, 2025 Termination Notice to “facilitate an *orderly* closeout” (emphasis added), in part by submitting all required detailed closeout reports identified, including a Final Performance/Progress Report, a Final Federal Financial Report, and an Equipment and Supplies – Tangible Personal Property Report. *See id.* To be clear, no “orderly” closeout of the Health Disparities Grant can reasonably be achieved in the 30-day period provided, notwithstanding the completion of the detailed reports required; moreover, additional costs will have to be incurred for the costs and burdens of strategically winding down Health Disparities Grant activities to minimize the devastating impact on the community partners that have come to depend on them.

37. Prior to the grant award termination, the CDC had never provided the notice, written or otherwise, that the grant administration had been in any way unsatisfactory.

38. While the impacts of the Health Disparities Grant termination are still being fully evaluated, the most immediate and distressing impact was the required termination of twenty-three (23) HRI-employed individuals, who worked in the Department’s Division of Family Health, Office for Minority Health and Health Disparities Prevention, and the Public Affairs Group.

39. The funding from the Health Disparities Grant was intended to engage with and empower community-based organizations across the state directly, consistent with the CDC’s approved activities within the intended scope of award. Communities that had never worked with the Department or any New York State government agency before received training and technical assistance to register and navigate the State’s procurement system and have now

executed contracts with New York State agencies as a direct result of the Health Disparities Grant. The Health Disparities Grant contracts have supported community-based organizations' ability to: 1) gain skills and knowledge about public health and to help them see that work they are doing is public health; and 2) develop and implement a project that draws upon the strengths of the community, meets the needs of the community, and utilizes solutions from the community. The Health Disparities Grant includes funding for capacity building for health literacy, as well as data collection and use.

40. Within the OPH's Center for Community Health, the Division of Family Health ("DFH") staff have led the efforts to implement equitable procurements in the form of small wellness grants (181), large wellness grants (19), and several vendor contracts for training and technical assistance, a community of practice for Community Health Workers, and support for five (5) mobile vehicles. In addition, staff have developed opportunities for community listening sessions using state-managed funds and a new federal grant with funding to support Medicaid enrollment, as well as writing a procurement for a new state appropriation for Children and Youth with Special Health Care Needs that would provide small community grants to increase accessibility and inclusivity.

41. Specifically, the loss of funds from the Health Disparities Grant will dismantle the Department's cornerstone achievement – the Small Wellness Mini Grants, totaling over \$9 million to 181 community-based organizations across New York State. The Department released funding in two cohorts. Cohort 1 resulted in contracts with 70 community-based organizations, awarding almost \$3.5M in total, with 61% being new partners to the Department. Cohort 2 resulted in 111 community-based organizations awarding a total of over \$5.5 million, with 92% being new partners to the Department.

42. Small Wellness Mini Grants were awarded in every county outside of New York City. The Department funded small community-based organizations that address issues like food insecurity, improving health literacy, youth and community empowerment, mental health, financial literacy, parent supports, physical activity, and faith-based organizations. The DFH has spent two to three years building relationships and trust with these diverse community members with the vision that we can work closely with them on the Department's broader work and especially in times of crisis, such as disease outbreaks or environmental/climate events.

43. The termination of the Health Disparities Grant has also resulted in the elimination of Large Community Wellness Grants, totaling \$4.75 million to 19 community-based organizations across New York State. Nineteen organizations were awarded \$250,000 with at least \$75,000 of the award allocated to a grassroots partner in their community. The goals are to: 1) build partnerships between large organizations and smaller grassroots organizations on a local level; and 2) provide another opportunity to build capacity for small community-based organizations. These grants are funded through the end of 2025 and were terminated prematurely, which will result in loss of funding for staff and the activities that are just now getting meaningfully started.

44. The termination of the Health Disparities Grant will also severely impact the Department's longer-term work of capacity building to help community-based organizations across New York State successfully register and navigate the New York State Statewide Financial System ("SFS") so that they can efficiently use the technology, access a broader pool of state funding opportunities from the Department as well as other New York State agencies. Most recently, DFH staff supported twenty-five (25) organizations in successfully registering in SFS. SFS can be complicated for these small organizations—the Department provided support and

intense technical assistance for months. Seventy (70) listening sessions with over 800 participants were held across thirty-three (33) counties.

45. The DFH is using this information to inform its five-year strategic action plan to support New York State's population from birth through reproductive age. The community-based organizations were trained to conduct community listening sessions and collect data in a uniform manner, and how to establish themselves in SFS and submit for reimbursement for State funding. The goal over the next year was to support additional organizations to enroll in SFS in the same manner. The Department was planning a statewide meeting in October 2025 to discuss sustainability activities, hoping to link community-based organizations pursuing new funding opportunities with their Local Health Departments.

46. In addition to the initiatives managed by the DFH, the Department's mission is supported by the Office of Minority Health and Health Disparities Prevention ("OMH-HDP"). The OMH-HDP's major activities aimed at capacity building, and anticipated impacts include disruptions to:

- a. The ability to effectively manage contracts, provide technical assistance and educational opportunities related to addressing health needs of New York State-recognized Tribal Nations. Under New York Public Health Law § 201(1)(s), the Department has a statutory obligation to "administer to the medical and health needs of the ambulant sick and needy Indians on the reservations". The Department satisfied this obligation through the New York State American Indian Health Program. Through establishment of contracts, contract management, educational opportunities, and technical assistance, OMH-HDP conducted

activities aimed at addressing the health needs of the Nations, Nation health clinics and health providers serving Nation members;

- b. Continuation of the Department's Rural Health Collaborative, which convened on an ad hoc basis to update programs across the Department about rural health initiatives and foster opportunities for collaboration, as well as a Lecture and Learn Series to educate Department staff and external stakeholders about population-based health; and
- c. Health literacy efforts within the Department and externally throughout the state to strengthen individual and organizational health literacy by promoting best practices, developing resources, and identifying strategies to make health communication more effective, within the Department and across New York State.

47. The Department relied and acted upon its expectation and understanding that the CDC would fulfill its commitment to provide the Health Disparities Grant it had already awarded. Likewise, recipients of the Community Wellness Mini Grants and Small Wellness Mini Grants have relied on the Department for continued funding and support of their own activities.

48. None of these activities will reach completion with the immediate termination of the Grant.

Immunization COVID-19 Supplemental Funding Grant

49. On June 5, 2020, the first Notice of Award ("NOA") for the COVID-19 Supplemental Funding Grant (Award No. 6 NH23IP922625-01-04) in the amount of \$5,277,968 was received from the CDC awarding funding under the base Immunization Vaccine For Children ("VFC") Cooperative Agreement, for a five year project period of July 1, 2019, to June

30, 2024. Unlike the other Grant Awards, DOH is the “Recipient” of the NOA. A copy of that NOA is attached hereto, as **Exhibit O**.

50. On September 23, 2020 the second Notice of Award (“NOA”) for the COVID-19 Supplemental Funding Grant (Award No. 6 NH23IP92262502-01) in the amount of \$7,825,598 was received from the CDC awarding funding under the base Immunization Vaccine For Children (“VFC”) Cooperative Agreement, for a five year project period of July 1, 2019, to June 30, 2024. A copy of that NOA is attached hereto, as **Exhibit P**.

51. Several NOAs were issued as COVID Supplemental Funding throughout the grant period thereafter including:

NOA Date	NOA No.	Document# s	Award value
6/5/2020	6 NH23IP922625-01-04	19NH23IP922625C3	\$5,277,968
9/23/2020	6 NH23IP922625-02-01	19NH23IP922625 20NH23IP922625C3	\$7,835,598
12/16/2020	6 NH23IP922625-02-02	20NH23IP922625C3	\$5,277,968
1/15/2021	6 NH23IP922625-02-03	20NH23IP922625C5	\$100,449,264
3/31/2021	6 NH23IP922625-02-04	20NH23IP922625C5 20NH23IP922625C6	\$100,449,263
5/3/2021	6 NH23IP922625-02-06	20NH23IP922625VWCC6	\$8,161,503

See **Exhibits O, P, Q, R, S, and T**, respectively.

52. NOA 6NH23IP922625-05-01 extended the grant period to December 31, 2024 (**Exhibit U**), and NOA 6NH23IP922625-05-09 further extended the grant period to June 30, 2025 (**Exhibit V**) which included approved carry over of \$55,834,475 in COVID supplemental funds. See **Exhibit W**.

53. On Tuesday, March 25, 2025, the Department received a notification, without any prior notice or indication, that the entire, base Immunization VFC Cooperative Agreement, was terminated effective retroactively to March 24, 2025 (6 NH23IP922625-05-10) (“March 24,

2025, Termination Notice”). A copy of the March 24, 2025 Termination Notice is attached hereto as **Exhibit X**.

54. The March 24, 2025, Termination Notice stated that the purpose, “is to terminate the use of any remaining COVID-19 funding associated with this award. The termination of this funding is for cause.” It further states that “[t]he end of the pandemic provides cause to terminate COVID-related grants and cooperative agreements [which]] were issued for a limited purpose: to ameliorate the effects of the pandemic.” It stated that “[n]ow that the pandemic is over, the grants and cooperative agreements are no longer necessary as their limited purpose has run out.” *See id.*

55. Apparently realizing it had erroneously terminated the entire Immunization VFC Cooperative Agreement rather than just the COVID-19 Supplemental Funding Grant with supplemental COVID-19 funding, on March 25, 2025, an updated message was received from the CDC, stating “On[sic] yesterday, March 24, 2025, the CDC issued Notices of Award to terminate certain COVID-19 funding, as directed. During that process, the Budget Period and Period of Performance dates were inadvertently changed to March 24, 2025 for the entire award. This was done in error and will be corrected by COB today. Thank[sic] you, Office[sic] of Grant Services.” *See Exhibit F*.

56. The CDC issued another NOA to the Department dated March 25, 2025, (6 NH23IP922625-05-11), which corrected the error and restored base grant (core) funding through June 30, 2025. A copy of the NOA is attached hereto as **Exhibit Y**.

57. The COVID-19 Supplemental Funding Grant was not originally supposed to terminate until the project end date of June 30, 2025, with a no-cost extension through June 30, 2027, submitted in February 2025 (which was under review but not yet awarded). Under this

extension, the Department was planning additional expenditures of approximately \$40M consistent with CDC's approved activities within the intended scope of award. A copy of this request is attached hereto as **Exhibit Z**.

58. The Department incurs expenses on grant awards established in the Statewide Financial System. These awards are established consistent with the Notice of Grant Awards provided from the sponsoring federal agency. The New York State Office of the Comptroller then routinely draws in reimbursement for these incurred expenses in the Federal Payment Management System.

59. Since the initial award, the Department has used the COVID-19 Supplemental Funding Grant funds in a manner fully consistent with approved activities within the intended scope of award.

60. New York State has been consistently in good standing with Immunization Cooperative Agreement activities and budgetary reporting.

61. Additionally, the March 24, 2025, Termination Notice stated that "[n]o additional activities can be conducted, and no additional costs can be incurred." Further, the Department was only provided thirty (30) days from the March 24, 2025 Termination Notice to submit final FFR's for impacted document numbers with funds authorized and expended for the report timeframe and balance of unobligated funds, when the Department usually has ninety (90) days past the end of the budget period to prepare the FFR. *See Exhibit X*.

62. Prior to the grant award termination, the CDC had never provided the Department with notice, written or otherwise, that the grant administration had been in any way unsatisfactory.

63. While the impacts of the COVID-19 Supplemental Funding Grant termination are still being fully evaluated, there are immediate consequences. For example, the Department is currently using this funding to contract out the maintenance of NYSIIS to an outside contractor to support immunization data infrastructure, consistent with CDC's approved activities within the intended scope of award. NYSIIS contains records of all New York State immunizations for children less than nineteen (19) years and some adults from healthcare providers, including vaccinations for COVID-19. PHL §§ 2168(1), (5), (13) explicitly charge the Department with implementing and maintaining the NYSIIS database. The existing contract is worth \$8.3 million.

64. The Department has a legal obligation and public health objective to protect the integrity of NYSIIS. NYSIIS also provides local health departments, healthcare providers, schools, and other entities complete, accurate, secure, real-time immunization data. If the maintenance contract is terminated and if any issues with the database, software, report, or data exchange with providers occur, then all authorized users, including the Department, local health departments, providers, schools and other entities will not have access to NYSIIS data to perform their state mandated vaccination activities and support patient care. In addition, providers will not be able to report vaccination data to NYSIIS, which will result in inaccurate and incomplete immunization records. Thus, there will be no reliable way to determine whether children are legitimately vaccinated to meet school vaccination requirements and ensure the health and safety of the community; nor would the Department have a reliable way to oversee the State's vaccination programs or comply with the legislature's statutory mandate. Even more alarming, the next outbreak of a deadly contagious diseases may not be able to be contained without accurate vaccination information to rely on. There will be critical impact on health and safety as providers, schools and other entities will not be able to verify patient immunization history from

NYSIIS. Additionally, there are staff and contractors in the Department's Bureau of Surveillance and Data Systems ("BSDS") that provide support to providers for mandated reporting and utilize NYSIIS to support patient vaccination.

65. COVID-19 Supplemental Funding Grant funds were also being used to fund a Vaccine Equity contract currently set to expire on June 30, 2025—aligned with the original COVID-19 Supplemental Funding Grant NOA termination date. This contract enables the contractor to sustain essential staffing levels to support local health departments' plans to prevent and respond to vaccine-preventable diseases, including COVID-19, provide high-quality vaccine positive social media content and translation services, support the Public Health Partnership Conference, continue the Vaccine Equity Lunch and Learn Series to coordinate vaccination efforts in areas with low immunization rates (e.g., COVID-19), and launch the "Stay in the Game" immunization campaign encouraging students to get their shots, including updated COVID-19. This funding is crucial to support local health departments in their mission to protect public health, fully consistent with CDC's approved activities within the intended scope of award. The Department's OPH has already requested a two year no-cost to CDC for an extension of this contract through June 30, 2027, committing an additional \$360,000 to this contract.

66. Further, there are existing contracts with the Tribal Nations funded by the COVID-19 Supplemental Funding Grant, overseen by the OMH-HDP in the amount of \$1.2 million. Funding was allocated to support New York State-recognized Tribal Nations and organizations in collaboration with Tribal Nations through programs that develop and implement community-based and culturally and linguistically appropriate messages that focus on COVID-

19 spread, symptoms, prevention and treatment, and the benefits of vaccination to support vaccine uptake in Tribal Nations.

67. An NYS-based educational research foundation (“Research Foundation”) was awarded funding to increase confidence levels in COVID-19 vaccines throughout the state. The Research Foundation work was spearheaded by two Nation community members to collaborate with Native leaders and other trusted community messengers to provide outreach, engagement, and education. The Research Foundation intended to create tailored culturally appropriate educational materials, messages, outreach events, and public service announcement.

68. One Tribal Nation’s project was an opportunity to meet the health and wellness needs of Tribal Nation community members. Year one, ending June 2024, resulted in members being identified as having Long COVID symptoms. Funding planned for 2025 sought to provide culturally sensitive information on self-management strategies for Long COVID and host a series of workshops and educational sessions through supportive environments for members affected by Long COVID. This funding supports workshops and educational sessions to educate and empower community members to recognize symptoms, seek appropriate support, and adopt lifestyle changes to manage their conditions effectively. Medical providers will be asked to present to the community to address various long COVID conditions. Members are encouraged to vaccinate and to promote vaccination within the community. Funding supports guest speakers, educational materials, and staff time to coordinate.

69. The funding was also used for the temporary services of two clinical nurses (approximately \$400,000 per year). One nurse supports regional immunization activities in the Western New York, including conducting CDC required on-site visits with providers enrolled in the Vaccines for Children Program. This includes assessment of COVID-19 vaccine stock

requirements to assure vaccine access for VFC eligible children. The other nurse supports clinical activities in the school immunization program, including providing education to school nurses and reviewing immunization medical exemption documentation.

70. There were also many activities that the Department had planned to imminently undertake with these grant funds, including but not limited to:

- a. Non-personnel services funding for building out a Bureau of Vaccine Confidence and Demand (\$300,000).
- b. The release of a proposed vaccine confidence Request for Applications (“RFA”), seeking to join with community-based partners and fund community collaborators trusted by close-knit vaccine hesitant communities to make house visits to discuss issues of vaccine safety and efficacy in plain language. Non-vaccination topics, including healthy pregnancy, milestones in child development, nutrition, and safety will also be discussed as trust is built (\$1.5 million).
- c. Media Campaigns, which created a statewide blitz of vaccine positive communication to stop misinformation from eroding public trust in vaccines; informed by and developed in partnership with community partners and trusted messengers to improve confidence in vaccines through culturally appropriate communication strategies (\$40 million).
- d. New York State Department of Health Behavioral Risk Factor Surveillance System contract amendment (\$1 million). The Behavioral Risk Factor Surveillance System (“BRFSS”) is an annual data collection program administered within the Department. Data is collected through random-digit dial telephone surveys supported by the Department in collaboration with the federal

Centers for Disease Control and Prevention. The BRFSS collects statewide information on health practices, risk behaviors and preventable conditions for the Department and its partners to use in program planning and evaluation. Topics include tobacco product use, physical activity, nutrition, vaccine hesitancy, and cancer screening, among others.

- e. A contract to form a five-part “Healthy Families, Healthy Kids” seminar, community level intervention delivered to mothers who are the primary decision makers on health matters in this focal community. A variety of topics about raising healthy children, of which vaccination is one, will be amplified. Continuous quality improvement activities will inform future iterations of these community level interventions and utility in other areas or close-knit communities with low immunization rates (\$350,000).

71. While the potential ramifications are still being assessed, there is also the very real risk that additional Department staff will need to be terminated as a part of any of these grant terminations.

72. The Department was always aware that the funding from these grants would end as of a date certain. Recognizing the significant funding these grants provided the Department, a careful and strategic approach to transitioning critical activities away from this funding and on to other funding is necessary. Many grants are time-limited and the Department has significant experience with effectuating such transitions; but, successful transition, without critical disruption of public health activities, is only possible when the original terms of the grant are honored. While the Department has experienced countless episodes of grants ending as per their original and designated timeline, the Department has no recent memory of ever having been

notified of a grant's termination not only with no advance notice, but *after* it had been terminated, as occurred here.

73. To be clear, these federal cuts are no less than a direct attack on the public health and safety of all New Yorkers.

I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge.

Executed this 28th Day of March 2025, in Albany, New York.

A handwritten signature in black ink, reading "Johanne E. Morne". The signature is written in a cursive style with a large, stylized 'J' and 'M'.

Johanne Morne

Executive Deputy Commissioner
NYS Department of Health

EXHIBIT A

1. DATE ISSUED MM/DD/YYYY 04/23/2020 1a. SUPERSEDES AWARD NOTICE dated 10/16/2019 #: 2523

except that any additions or restrictions previously imposed remain in effect unless specifically rescinded

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

2. CFDA NO. 93.323 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	
3. ASSISTANCE TYPE Cooperative Agreement	
4. GRANT NO. 6 NU50CK000516-01-06 Formerly	5. TYPE OF AWARD Demonstration
4a. FAIN NU50CK000516	5a. ACTION TYPE Post Award Amendment
6. PROJECT PERIOD MM/DD/YYYY From 08/01/2019	Through 07/31/2024
7. BUDGET PERIOD MM/DD/YYYY From 08/01/2019	Through 07/31/2020

8. TITLE OF PROJECT (OR PROGRAM)
Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases in New York State

9a. GRANTEE NAME AND ADDRESS HEALTH RESEARCH, INC. 150 BROADWAY STE 560 -DUP4 MENANDS, NY 12204-2719	9b. GRANTEE PROJECT DIRECTOR Ms. DEBRA S. BLOG M.D. Empire State Plaza Corning Tower, Room 503 Albany, NY 12237 Phone: 518-474-4394
--	---

10a. GRANTEE AUTHORIZING OFFICIAL Mr. Michael A. Saglimbeni 150 Broadway Suite 560 Riverview Center Menands, NY 12204-2719	10b. FEDERAL PROJECT OFFICER Wayne Brathwaite 1600 Clifton Rd Atlanta, GA 30333 Phone: 404-639-5127
--	---

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)		12. AWARD COMPUTATION	
I Financial Assistance from the Federal Awarding Agency Only		a. Amount of Federal Financial Assistance (from item 11m) 29,168,410.00	
II Total project costs including grant funds and all other financial participation I		b. Less Unobligated Balance From Prior Budget Periods 0.00	
a. Salaries and WageS 4,246,864.00		c. Less Cumulative Prior Award(s) This Budget Period 10,623,655.00	
b. Fringe Benefits 1,583,174.00		d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 18,544,755.00	
c. Total Personnel Costs 5,830,038.00		13. Total Federal Funds Awarded to Date for Project Period 29,168,410.00	
d. Equipment 55,000.00		14. RECOMMENDED FUTURE SUPPORT (Subject to the availability of funds and satisfactory progress of the project):	
e. Supplies 1,052,571.00		YEAR TOTAL DIRECT COSTS YEAR TOTAL DIRECT COSTS	
f. Travel 186,020.00		a. 2 b. 3 c. 4 d. 5 e. 6 f. 7	
g. Construction 0.00		15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:	
h. Other 19,002,473.00		a. DEDUCTION	
i. Contractual 702,646.00		b. ADDITIONAL COSTS	
j. TOTAL DIRECT COSTS 26,828,748.00		c. MATCHING	
k. INDIRECT COSTS 2,339,662.00		d. OTHER RESEARCH (Add / Deduct Option)	
l. TOTAL APPROVED BUDGET 29,168,410.00		e. OTHER (See REMARKS)	
m. Federal Share 29,168,410.00		16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:	
n. Non-Federal Share 0.00		a. The grant program legislation	
		b. The grant program regulations.	
		c. This award notice including terms and conditions, if any, noted below under REMARKS.	
		d. Federal administrative requirements, cost principles and audit requirements applicable to the grant.	
		In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.	

REMARKS (Other Terms and Conditions Attached -

☒ Yes☐ No

GRANTS MANAGEMENT OFFICIAL:

Brownie Anderson-Rana, Grants Management Officer
2939 Flowers Road
Mailstop TV2
Atlanta, GA 30341-5509
Phone: 770-488-2771

17.OBJ CLASS 41.51	18a. VENDOR CODE 1141402155A1	18b. EIN 141402155	19. DUNS 002436061	20. CONG. DIST. 20
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
21. a. 0-9390EWQ	b. 19NU50CK000516C3	c. CK	d. \$18,544,755.00	e. 75-2024-0943
22. a.	b.	c.	d.	e.
23. a.	b.	c.	d.	e.

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 04/23/2020
GRANT NO. 6 NU50CK000516-01-06	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 04/23/2020
GRANT NO. 6 NU50CK000516-01-06	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
08/01/2019	07/31/2020	Annual	10/29/2020

AWARD ATTACHMENTS

Health Research, Inc.

6 NU50CK000516-01-06

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, entitled Epidemiology and Laboratory Capacity (ELC), which is hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Component Funding: Additional funding in the amount \$18,544,755 is approved for the Year 01 budget period, which is August 1, 2019 through July 31, 2020 **COVID-19** Response Activities:

- E. Cross-Cutting Emerging Issues: \$18,544,755

Recipients have 24 months from the date of this NoA to expend all funds awarded herein

Budget/Workplan Revision Requirement: Within 30 days of this NoA, the recipient must submit a revised budget with a narrative justification outlining response activities. Failure to submit the required information in a timely manner may adversely affect the future funding of the project. If the information cannot be provided by the due date, you are required to contact your ELC Project Officer and Grant Management Specialist. Revised budget can be uploaded in GrantSolutions as a grant note for the purpose of “administrative relief” during the COVID-19 crisis.

Pre-Award Costs: Pre-award costs dating back to January 20, 2020 – when CDC first activated its Emergency Operations Center (EOC) – and directly related to the COVID-19 outbreak response are allowable.

Indirect Costs: Indirect cost will be approved based on current approved negotiated indirect cost rate agreement.

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees’ time and effort.

Additional Reporting:

- Monthly progress reports on status of timelines, goals, and objectives as defined by CDC in approved work plans.
- Monthly fiscal reports (beginning 60 days after NOAs are issued).
- Performance measure data
- CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required.

Additional Term and Condition:

A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123) or the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the “CARES Act”) (P.L. 116-136) agrees to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread

of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

If recipient disburses any funds received pursuant to this award to a local jurisdiction, recipient shall ensure that the local jurisdiction complies with the terms and conditions of this award. Consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, to the extent applicable, Recipient will comply with Section 18115 of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"), Public Law 116-136, with respect to the reporting to the Secretary of Health and Human Services of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Tonya M. Jenkins, Grants Management Specialist
Time Solutions LLC
Office of Grants Services (OGS)
Office of Financial Resources (OFR)
Office of the Chief Operating Officer (OCOO)
Centers for Disease Control and Prevention (CDC)
pjo6@cdc.gov | 404-498-2399 office

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1- 800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhtips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT B

1. DATE ISSUED MM/DD/YYYY 07/15/2019
1a. SUPERSEDES AWARD NOTICE dated #: 2532
except that any additions or restrictions previously imposed remain in effect unless specifically rescinded

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
CDC Office of Financial Resources

2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

2. CFDA NO. 93.323 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	
3. ASSISTANCE TYPE Cooperative Agreement	
4. GRANT NO. 1 NU50CK000516-01-00 Formerly	5. TYPE OF AWARD Other
4a. FAIN NU50CK000516	5a. ACTION TYPE New
6. PROJECT PERIOD MM/DD/YYYY From 08/01/2019	Through 07/31/2024
7. BUDGET PERIOD MM/DD/YYYY From 08/01/2019	Through 07/31/2020

8. TITLE OF PROJECT (OR PROGRAM)
Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases in New York State

9a. GRANTEE NAME AND ADDRESS HEALTH RESEARCH, INC. 150 Broadway Ste 560 -DUP4 Menands, NY 12204-2719	9b. GRANTEE PROJECT DIRECTOR Ms. DEBRA S. BLOG M.D. Empire State Plaza Corning Tower, Room 503 Albany, NY 12237 Phone: 518-474-4394
--	---

10a. GRANTEE AUTHORIZING OFFICIAL Mr. Michael A. Saglimbeni 150 Broadwat Suite 560 Riverview Center Menands, NY 12204-2719	10b. FEDERAL PROJECT OFFICER Wayne Brathwaite 1600 Clifton Rd Atlanta, GA 30333 Phone: 404-639-5127
--	---

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)		12. AWARD COMPUTATION	
I Financial Assistance from the Federal Awarding Agency Only		a. Amount of Federal Financial Assistance (from item 11m) 8,649,332.00	
II Total project costs including grant funds and all other financial participation		b. Less Unobligated Balance From Prior Budget Periods 0.00	
		c. Less Cumulative Prior Award(s) This Budget Period 0.00	
		d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 8,649,332.00	
		13. Total Federal Funds Awarded to Date for Project Period 8,649,332.00	
		14. RECOMMENDED FUTURE SUPPORT (Subject to the availability of funds and satisfactory progress of the project):	
		YEAR TOTAL DIRECT COSTS YEAR TOTAL DIRECT COSTS	
		a. 2 b. 3 c. 4 d. 5 e. 6 f. 7	
		15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:	
		a. DEDUCTION b. ADDITIONAL COSTS c. MATCHING d. OTHER RESEARCH (Add / Deduct Option) e. OTHER (See REMARKS)	
		b	
		16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDOING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:	
		a. The grant program legislation b. The grant program regulations. c. This award notice including terms and conditions, if any, noted below under REMARKS. d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.	
		In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.	

REMARKS (Other Terms and Conditions Attached - ☒ Yes ☐ No)
Approved funding for year 1 in the amount of \$8,649,332, of which \$350,000 is Ebola funding and \$30,418 is Hurricane funding.

GRANTS MANAGEMENT OFFICIAL:

Shirley K Byrd, Grants Management Officer
2939 Flowers Rd
Mailstop TV-2
Atlanta, GA 30341-5509
Phone: (770) 488-2591

17.OBJ CLASS	41.51	18a. VENDOR CODE	1141402155A1	18b. EIN	141402155	19. DUNS	002436061	20. CONG. DIST.	20
FY-ACCOUNT NO.		DOCUMENT NO.		ADMINISTRATIVE CODE		AMT ACTION FIN ASST		APPROPRIATION	
21. a.	9-9211765	b.	19NU50CK000516	c.	CK	d.	\$16,150.00	e.	75-19-0949
22. a.	9-921VV46	b.	19NU50CK000516	c.	CK	d.	\$404,186.00	e.	75-19-0949
23. a.	9-921VV47	b.	19NU50CK000516	c.	CK	d.	\$96,200.00	e.	75-19-0949

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 07/15/2019
GRANT NO. 1 NU50CK000516-01-00	

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
24.a. 9-921ZCTK	b. 19NU50CK000516	c. CK	d. \$37,786.00	e. 75-19-0949
25.a. 9-939014P	b. 19NU50CK000516	c. CK	d. \$293,972.00	e. 75-19-0949
26.a. 9-93902Z0	b. 19NU50CK00051619EBLA	c. CK	d. \$350,000.00	e. 75-1519-0943
27.a. 9-93903FA	b. 19NU50CK000516	c. CK	d. \$8,000.00	e. 75-19-0949
28.a. 9-93905VH	b. 19NU50CK000516	c. CK	d. \$316,421.00	e. 75-19-0949
29.a. 9-93906EZ	b. 19NU50CK000516	c. CK	d. \$90,000.00	e. 75-19-0947
30.a. 9-93908MV	b. 19NU50CK000516	c. CK	d. \$3,350,926.00	e. 75-19-0949
31.a. 9-93909PE	b. 19NU50CK000516	c. CK	d. \$16,458.00	e. 75-X-0951
32.a. 9-93909PG	b. 19NU50CK000516	c. CK	d. \$29,549.00	e. 75-X-0951
33.a. 9-93909QZ	b. 19NU50CK000516	c. CK	d. \$191,380.00	e. 75-X-0951
34.a. 9-93909R9	b. 19NU50CK000516	c. CK	d. \$60,659.00	e. 75-19-0949
35.a. 9-93909UW	b. 19NU50CK000516	c. CK	d. \$1,232,705.00	e. 75-X-0949
36.a. 9-9390AC3	b. 19NU50CK00051619HURR	c. CK	d. \$30,418.00	e. 75-1820-0943
37.a. 9-9390BW5	b. 19NU50CK000516	c. CK	d. \$425,000.00	e. 75-19-0958
38.a. 9-9390C0K	b. 19NU50CK000516	c. CK	d. \$134,754.00	e. 75-X-0943
39.a. 9-9390CA2	b. 19NU50CK000516	c. CK	d. \$220,926.00	e. 75-19-0952
40.a. 9-939ZL BG	b. 19NU50CK000516	c. CK	d. \$6,100.00	e. 75-19-0951
41.a. 9-939ZRQB	b. 19NU50CK000516	c. CK	d. \$14,000.00	e. 75-19-0950
42.a. 9-939ZSCE	b. 19NU50CK000516	c. CK	d. \$134,449.00	e. 75-19-0951
43.a. 9-939ZSKR	b. 19NU50CK000516	c. CK	d. \$85,253.00	e. 75-19-0949
44.a. 9-939ZVJC	b. 19NU50CK000516	c. CK	d. \$1,104,040.00	e. 75-19-0949

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 07/15/2019
GRANT NO. 1 NU50CK000516-01-00	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
08/01/2019	07/31/2020	Annual	10/29/2020
08/01/2020	07/31/2021	Annual	10/29/2021
08/01/2021	07/31/2022	Annual	10/29/2022
08/01/2022	07/31/2023	Annual	10/29/2023
08/01/2023	07/31/2024	Annual	10/29/2024

AWARD ATTACHMENTS

Health Research, Inc.

1 NU50CK000516-01-00

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-CK19-1904, entitled 2019 Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC) - 2019, and application dated May 8, 2019, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of **\$8,649,332** is approved for the Year 01 budget period, which is August 1, 2019 through July 31, 2020. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

NOFO Funding	Amount
Non-PPHF	\$ 8,268,914
Hurricane	\$ 30,418
Ebola	\$ 350,000

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Hurricane Disaster Relief Funds and Availability: Funds for grants provided by division B of Public Law 115-56, division A of Public Law 115-72, and division B of Public Law 115-123 must be expended by grant recipients within the 24-month period following the agency's obligation of those funds. The agency obligation date is identified as the Issue Date reflected on page one of this Notice of Award.

Funding in the amount of **\$30,418** is approved for budget period **August 1, 2019** through **July 31, 2020**. The recipient must expend and disburse all funds by **July 31, 2021**. After the budget period has expired, CDC may de-obligate all funds not expended and disbursed, including unliquidated obligations.

Note: Refer to the Payment Information section for draw down and Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

CDC program staff will assist, coordinate, or participate in carrying out effort under the award, and recipients agree to the responsibilities therein, as detailed in the NOFO.

Objective/Technical Review Statement Response Requirement: The review comments on

the strengths and weaknesses of the proposal are provided as part of this award. A response to the weaknesses in these statements must be submitted to and approved, in writing, by the Program Officer noted in the CDC Staff Contacts section of this NoA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, September 2, 2019, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

- ☒ Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

Program Income: Any program income generated under this grant or cooperative agreement will be used in accordance with the Addition alternative.

Addition alternative: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Hurricane Disaster Previously Incurred Costs Restrictions: Previously incurred costs and activities that will be reimbursed or funded by another federal source (e.g., FEMA) may not be included.

Indirect Costs: Indirect costs are approved based on the negotiated indirect cost rate agreement dated November 8, 2018, which calculates indirect costs as follows, a Provisional rate is approved at a rate of 20.6% of the base, which includes, direct salaries and wages including all fringe benefits. The effective dates of this indirect cost rate are from April 1, 2019 to March 31, 2021.

REPORTING REQUIREMENTS

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under **OMB Number 0920-1132, "Performance Progress and Monitoring Report", Expiration Date 8/31/2019**. The components of the PPMR are available for download at: <https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html> .

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity

violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Karen Zion, Grants Management Specialist
Centers for Disease Control and Prevention
Infectious Disease Services Branch
2939 Flowers Road, MS-TV-2
Atlanta, GA 30341
Telephone: 770-488-2729
Email: wvf8@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Component: Non-PPHF
Document Number: 19NU50CK000516

Component: Hurricane
Document Number: 19NU50CK00051619HURR

Component: Ebola
Document Number: 19NU50CK00051619EBLA

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:

Karen Zion, Grants Management Specialist
Centers for Disease Control and Prevention
Infectious Disease Services Branch
2939 Flowers Road, MS-TV-2
Atlanta, GA 30341
Telephone: 770-488-2729
Email: wvf8@cdc.gov

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

EXHIBIT C

1. DATE ISSUED MM/DD/YYYY 05/18/2020 1a. SUPERSEDES AWARD NOTICE dated 04/23/2024 #: 2541

except that any additions or restrictions previously imposed remain in effect unless specifically rescinded

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

2. CFDA NO. 93.323 - Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)	
3. ASSISTANCE TYPE Cooperative Agreement	
4. GRANT NO. 6 NU50CK000516-01-07 Formerly	5. TYPE OF AWARD Demonstration
4a. FAIN NU50CK000516	5a. ACTION TYPE Post Award Amendment
6. PROJECT PERIOD MM/DD/YYYY From 08/01/2019	Through 07/31/2024
7. BUDGET PERIOD MM/DD/YYYY From 08/01/2019	Through 07/31/2020

8. TITLE OF PROJECT (OR PROGRAM)
Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases in New York State

9a. GRANTEE NAME AND ADDRESS

HEALTH RESEARCH, INC.
150 BROADWAY STE 560
-DUP4
MENANDS, NY 12204-2719

9b. GRANTEE PROJECT DIRECTOR

Ms. DEBRA S. BLOG M.D.
Empire State Plaza Corning Tower, Room 503
Albany, NY 12237
Phone: 518-474-4394

10a. GRANTEE AUTHORIZING OFFICIAL

Mr. Michael A. Saglimbeni
150 Broadway Suite 560
Riverview Center
Menands, NY 12204-2719

10b. FEDERAL PROJECT OFFICER

Mr. Wayne Brathwaite
1600 Clifton Rd
C-18
Division of Preparedness and Emerging Infections
Atlanta, GA 30333

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)

I Financial Assistance from the Federal Awarding Agency Only

II Total project costs including grant funds and all other financial participation

I

a. Salaries and WageS	4,246,864.00
b. Fringe Benefits	1,583,174.00
c. Total Personnel Costs	5,830,038.00
d. Equipment	55,000.00
e. Supplies	1,052,571.00
f. Travel	186,020.00
g. Construction	0.00
h. Other	719,251,455.00
i. Contractual	702,646.00
j. TOTAL DIRECT COSTS	727,077,730.00
k. INDIRECT COSTS	2,339,662.00
l. TOTAL APPROVED BUDGET	729,417,392.00
m. Federal Share	729,417,392.00
n. Non-Federal Share	0.00

12. AWARD COMPUTATION

a. Amount of Federal Financial Assistance (from item 11m)	729,417,392.00
b. Less Unobligated Balance From Prior Budget Periods	0.00
c. Less Cumulative Prior Award(s) This Budget Period	29,168,410.00
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION	700,248,982.00

13. Total Federal Funds Awarded to Date for Project Period 729,417,392.00

14. RECOMMENDED FUTURE SUPPORT

(Subject to the availability of funds and satisfactory progress of the project):

YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS
a. 2		d. 5	
b. 3		e. 6	
c. 4		f. 7	

15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:

- a. DEDUCTION
- b. ADDITIONAL COSTS
- c. MATCHING
- d. OTHER RESEARCH (Add / Deduct Option)
- e. OTHER (See REMARKS)

b

16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:

- a. The grant program legislation
- b. The grant program regulations.
- c. This award notice including terms and conditions, if any, noted below under REMARKS.
- d. Federal administrative requirements, cost principles and audit requirements applicable to the grant.

In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.

REMARKS (Other Terms and Conditions Attached -

☒ Yes☐ No)

ELC Enhancing Detection Funding: Financial Assistance in the amount of \$700,248,982

GRANTS MANAGEMENT OFFICIAL:

Brownie Anderson-Rana, Grants Management Officer
2939 Flowers Road
Mailstop TV2
Atlanta, GA 30341-5509
Phone: 770-488-2771

17.OBJ CLASS 41.51	18a. VENDOR CODE 1141402155A1	18b. EIN 141402155	19. DUNS 002436061	20. CONG. DIST. 20
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
21. a. 0-9390F7F	b. 19NU50CK000516C4	c. CK	d. \$700,248,982.00	e. 75-X-0140
22. a.	b.	c.	d.	e.
23. a.	b.	c.	d.	e.

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 05/18/2020
GRANT NO. 6 NU50CK000516-01-07	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 05/18/2020
GRANT NO. 6 NU50CK000516-01-07	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
08/01/2019	07/31/2020	Annual	10/29/2020

AWARD ATTACHMENTS

Health Research, Inc.

6 NU50CK000516-01-07

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, entitled Epidemiology and Laboratory Capacity (ELC), which is hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Component Funding: Additional funding in the amount \$700,248,982 is approved for the Year 01 budget period, which is August 1, 2019 through July 31, 2020

COVID-19 Paycheck Protection Program and Health Care Enhancement Act Response Activities:

E. Cross-Cutting Emerging Issues: \$700,248,982

Recipients have **30 months** from the date of this NoA to expend all funds awarded herein

Budget/Workplan Revision Requirement: Within 30 days of this NoA, the recipient must submit a revised budget with a narrative justification outlining response activities. Failure to submit the required information in a timely manner may adversely affect the future funding of the project. If the information cannot be provided by the due date, you are required to contact your ELC Project Officer and Grant Management Specialist. The revised budget must be uploaded in GrantSolutions as an amendment to allow issuance of a revised NoA.

Pre-Award Costs: Pre-award costs dating back to January 20, 2020 – when CDC first activated its Emergency Operations Center (EOC) – and directly related to the COVID-19 outbreak response are allowable.

Indirect Costs: Indirect cost will be approved based on current approved negotiated indirect cost rate agreement.

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Additional Term and Condition:

A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the

purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- ***All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.***

REPORTING REQUIREMENTS

Additional Reporting:

- Monthly fiscal reports (beginning 60 days after NOAs are issued)
- Quarterly progress reports on status of timelines, goals, and objectives as defined by CDC in approved work plans
- Quarterly Performance measure data
- CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required.
- Quarterly reporting of test results, both positive and negative
- Clarity on how the states will focus on high socially vulnerable index counties, rural and urban areas, etc. (Vulnerable populations must be specific).

Required Disclosures for Federal Awardee Performance and Integrity Information System

(FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the

following addresses:

CDC, Office of Grants Services
Tonya M. Jenkins, Grants Management Specialist
Time Solutions LLC
Office of Grants Services (OGS)
Office of Financial Resources (OFR)
Office of the Chief Operating Officer (OCOO)
Centers for Disease Control and Prevention (CDC)
pjo6@cdc.gov | 404-498-2399 office

AND

U.S. Department of Health and Human Services Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator 330 Independence Avenue, SW
Cohen Building, Room 5527 Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email:
MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1- 800-HHS- TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT D



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000516-02-05

FAIN# NU50CK000516

Federal Award Date: 01/14/2021

Recipient Information**1. Recipient Name**

Health Research, Inc.
150 BROADWAY STE 560
-DUP4
MENANDS, NY 12204-2719
[No Phone Record]

2. Congressional District of Recipient

20

3. Payment System Identifier (ID)

1141402155A1

4. Employer Identification Number (EIN)

141402155

5. Data Universal Numbering System (DUNS)

002436061

6. Recipient's Unique Entity Identifier**7. Project Director or Principal Investigator**

Ms. DEBRA S. BLOG M.D.
debra.blog@health.ny.gov
518-474-4394

8. Authorized Official

Mr. Michael A. Saglimbeni
Director of Sponsored Programs
michael.saglimbeni@healthresearch.org
518-431-1200

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Ms. Kathy Raible-GMS
kcr8@cdc.gov
770-488-2045

10. Program Official Contact Information

Mr. Fred Maxineau
PHA
hyx2@cdc.gov
404.639.0869

Federal Award Information**11. Award Number**

6 NU50CK000516-02-05

12. Unique Federal Award Identification Number (FAIN)

NU50CK000516

13. Statutory Authority

301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

14. Federal Award Project Title

Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases in New York State

15. Assistance Listing Number

93.323

16. Assistance Listing Program Title

Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 08/01/2020 **- End Date** 07/31/2021**20. Total Amount of Federal Funds Obligated by this Action** \$639,861,809.00

20a. Direct Cost Amount \$639,861,809.00

20b. Indirect Cost Amount \$0.00

21. Authorized Carryover \$0.00**22. Offset** \$0.00**23. Total Amount of Federal Funds Obligated this budget period** \$13,499,162.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$653,360,971.00**26. Project Period Start Date** 08/01/2019 **- End Date** 07/31/2024**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period** \$1,386,773,375.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Brownie Anderson-Rana
Grants Management Officer

30. Remarks



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000516-02-05

FAIN# NU50CK000516

Federal Award Date: 01/14/2021

Recipient Information**Recipient Name**

Health Research, Inc.
150 BROADWAY STE 560
-DUP4
MENANDS, NY 12204-2719
[No Phone Record]

Congressional District of Recipient

20

Payment Account Number and Type

1141402155A1

Employer Identification Number (EIN) Data

141402155

Universal Numbering System (DUNS)

002436061

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Cooperative Agreement

32. Type of Award

Demonstration

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$4,248,463.00
b. Fringe Benefits	\$1,604,117.00
c. Total Personnel Costs	\$5,852,580.00
d. Equipment	\$52,251.00
e. Supplies	\$927,531.00
f. Travel	\$74,722.00
g. Construction	\$0.00
h. Other	\$643,271,004.00
i. Contractual	\$850,786.00
j. TOTAL DIRECT COSTS	\$651,028,874.00
k. INDIRECT COSTS	\$2,332,097.00
l. TOTAL APPROVED BUDGET	\$653,360,971.00
m. Federal Share	\$653,360,971.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390GKT	19NU50CK000516EDEXC5	CK	41.51	\$639,861,809.00	75-2122-0140
0-9390EUT	19NU50CK000516	CK	41.51	\$0.00	75-20-0959



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000516-02-05

FAIN# NU50CK000516

Federal Award Date: 01/14/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Health Research, Inc.

6 NU50CK000516-02-05

1. Revised Terms & Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CK19-1904, entitled Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases (ELC), which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount \$639,861,809 is approved for the Year 02 budget period, which is August 1, 2020 through July 31, 2021.

The approved component and funding level for this notice of award are:

NOFO Component	Amount
ELC Enhancing Detection Expansion	\$639,861,809

Recipients have until July 31, 2023 to expend all COVID-19 funds awarded herein.

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); and/or the Consolidated Appropriations Act, 2021, Division M – Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260), agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

To achieve the public health objectives of ensuring the health, safety, and welfare of all Americans, Recipient must distribute or administer vaccine without discriminating on non-public-health grounds within a prioritized group. This includes, but is not limited to, immigration status, criminal history, incarceration, or homelessness. To this end, and to help achieve the public health imperative of widespread herd immunity to COVID-19, Recipient must administer or distribute vaccine to any and all individuals within a prioritized group in the same timeframe, taking into account available vaccine doses. For example, if meatpacking plant workers are a prioritized group, then all workers in that group, including undocumented immigrants, must be vaccinated to help assure that the plant is in a position to safely resume essential functions.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting [guidance](https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf) is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients: https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf

- All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

Budget Revision Requirement: By March 17, 2021 the recipient must submit a separate revised budget with a narrative justification and workplan in accordance with the COVID-19 guidance. The workplan should be submitted in REDCap and must address all activities in the guidance.

The revised budget and narrative justification must be uploaded as an amendment in Grant Solutions with a SF424A.

Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

REPORTING REQUIREMENTS

COVID-19 - Additional Reporting Requirements:

- Monthly fiscal reports (beginning 60 days after NOAs are issued). Thereafter, all monthly financial reporting will occur on the 5th of the month which will cover the preceding month's expenditures and unliquidated obligations (ULOs).
- Quarterly workplan milestone progress reporting will start on April 30, 2021; and will follow the regular ELC quarterly reporting timeline.
- The Jurisdictional Testing, Case Investigation, and Contact Tracing Plan updates will occur on the same quarterly reporting timeline as the workplan milestone progress.
- CDC may require recipients to develop annual progress reports (APRs). CDC will provide APR guidance and optional templates should they be required

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Kathy Raible, Grants Management Specialist

Centers for Disease Control and
Prevention Branch 1
2939 Flowers Road, MS-TV2
Atlanta, GA 30341
Email: kcr8@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosure, Intake Coordinator
330 Independent Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1- 800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the

NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Stewardship Information

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT E

**Recipient Information****1. Recipient Name**

HEALTH RESEARCH, INC.

150 BROADWAY STE 560

-DUP4

MENANDS, NY 12204-2719

[No Phone Record]

2. Congressional District of Recipient

20

3. Payment System Identifier (ID)

1141402155A1

4. Employer Identification Number (EIN)

141402155

5. Data Universal Numbering System (DUNS)

002436061

6. Recipient's Unique Entity Identifier (UEI)

G9H6SUM59YC4

7. Project Director or Principal Investigator

Dr. Emily Lutterloh

emily.lutterloh@health.ny.gov

518-474-1142

8. Authorized Official

Mr. Michael A. Saglimbeni

Director of Sponsored Programs

HRINGA@healthresearch.org

518-431-1200

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Whitney Dade

Grants Management Specialist

zmm8@cdc.gov

4044983038

10. Program Official Contact Information

Yonathan Gebru

Program Officer

qnw9@cdc.gov

6784272383

Federal Award Information**11. Award Number**

6 NU50CK000516-05-11

12. Unique Federal Award Identification Number (FAIN)

NU50CK000516

13. Statutory Authority

301(A)AND317(K)(2)PHS42USC241(A)247B(K)2

14. Federal Award Project Title

Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases in New York State

15. Assistance Listing Number

93.323

16. Assistance Listing Program Title

Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)

17. Award Action Type

Administrative Action

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 08/01/2023 - **End Date** 03/24/2025**20. Total Amount of Federal Funds Obligated by this Action**

\$0.00

20a. Direct Cost Amount

\$0.00

20b. Indirect Cost Amount

\$0.00

21. Authorized Carryover

\$72,338,485.00

22. Offset

\$2,071,173.00

23. Total Amount of Federal Funds Obligated this budget period

\$16,288,452.00

24. Total Approved Cost Sharing or Matching, where applicable

\$0.00

25. Total Federal and Non-Federal Approved this Budget Period

\$16,288,452.00

26. Period of Performance Start Date 08/01/2019 - **End Date** 03/24/2025**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance**

\$1,663,306,245.50

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Terrian Dixon

Grants Management Officer

30. Remarks

Department Authority



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000516-05-11

FAIN# NU50CK000516

Federal Award Date: 03/24/2025

Recipient Information**Recipient Name**

HEALTH RESEARCH, INC.
150 BROADWAY STE 560
-DUP4
MENANDS, NY 12204-2719
[No Phone Record]

Congressional District of Recipient

20

Payment Account Number and Type

1141402155A1

Employer Identification Number (EIN) Data

141402155

Universal Numbering System (DUNS)

002436061

Recipient's Unique Entity Identifier (UEI)

G9H6SUM59YC4

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$15,357,445.00
b. Fringe Benefits	\$6,037,815.00
c. Total Personnel Costs	\$21,395,260.00
d. Equipment	\$3,933,415.00
e. Supplies	\$3,709,875.00
f. Travel	\$175,365.00
g. Construction	\$0.00
h. Other	\$4,771,369.00
i. Contractual	\$47,751,715.00
j. TOTAL DIRECT COSTS	\$81,736,999.00
k. INDIRECT COSTS	\$8,961,111.00
l. TOTAL APPROVED BUDGET	\$90,698,110.00
m. Federal Share	\$90,698,110.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	ASSISTANCE LISTING	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
0-9390EPX	19NU50CK000516CV	CK	41.51	93.323	\$0.00	75-2022-0943
0-9390F7F	19NU50CK000516C4	CK	41.51	93.323	\$0.00	75-X-0140
1-9390GKT	19NU50CK000516EDEXC5	CK	41.51	93.323	\$0.00	75-2122-0140



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000516-05-11

FAIN# NU50CK000516

Federal Award Date: 03/24/2025

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH RESEARCH, INC.

6 NU50CK000516-05-11

1. Terms and Conditions

TERMS AND CONDITIONS OF AWARD

Termination: The purpose of this amendment is to terminate the use of any remaining COVID-19 funding associated with this award. The termination of this funding is for cause. HHS regulations permit termination if “the non-Federal entity fails to comply with the terms and conditions of the award”, or separately, “for cause.” The end of the pandemic provides cause to terminate COVID-related grants and cooperative agreements. These grants and cooperative agreements were issued for a limited purpose: to ameliorate the effects of the pandemic. Now that the pandemic is over, the grants and cooperative agreements are no longer necessary as their limited purpose has run out. Termination of use of funding under the listed document number(s) is effective as of the date set out in your Notice of Award.

Impacted document numbers are included on page 2 of this Notice of Award (NoA).

No additional activities can be conducted, and no additional costs may be incurred, as it relates to these funds. Unobligated award balances of COVID-19 funding will be de-obligated by CDC. Award activities under other funding may continue consistent with the terms and conditions of the award.

Final Federal Financial Report (FFR, SF-425): Within 30 days please submit final FFR’s for impacted document numbers. The FFR should only include those funds authorized and expended during the timeframe covered by the report. The final report must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. Should the amount not match with the final expenditures reported to the Payment Management System (PMS), you will be required to update your reports to PMS accordingly.

All other terms and conditions of this award remain in effect.

EXHIBIT F

AUTHOR	MESSAGE	DATE / TIME	ACTIONS
Shirley Byrd	On yesterday, March 24, 2025, CDC issued Notices of Award to terminate certain COVID-19 funding, as directed. During that process, the Budget Period and Period of Performance dates were inadvertently changed to March 24, 2025 for the entire award. This was done in error and will be corrected by COB today.Thank you,Office of Grant Services	03/25/2025 01:21 PM EST	

EXHIBIT G

**Recipient Information****1. Recipient Name**

HEALTH RESEARCH, INC.
150 BROADWAY STE 560
-DUP4
MENANDS, NY 12204-2719
[No Phone Record]

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**
1141402155A1**4. Employer Identification Number (EIN)**
141402155**5. Data Universal Numbering System (DUNS)**
002436061**6. Recipient's Unique Entity Identifier (UEI)**
G9H6SUM59YC4**7. Project Director or Principal Investigator**

Dr. Emily Lutterluh
emily.lutterluh@health.ny.gov
518-474-1142**8. Authorized Official**

Mr. Michael A. Saglimbeni
Director of Sponsored Programs
michael.saglimbeni@healthresearch.org
518-431-1200

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Ryan Smythe
Grants Management Specialist
lyt6@cdc.gov
(770) 488-3629

10. Program Official Contact Information

Namita Agravat
Program Officer
nfk0@cdc.gov
6784310843

Federal Award Information**11. Award Number**

6 NU50CK000516-05-02

12. Unique Federal Award Identification Number (FAIN)
NU50CK000516**13. Statutory Authority**
301(A)AND317(K)(2)PHS42USC241(A)247B(K)2**14. Federal Award Project Title**

Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases in New York State

15. Assistance Listing Number
93.323**16. Assistance Listing Program Title**
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC)**17. Award Action Type**
No Cost Extension**18. Is the Award R&D?**
No**Summary Federal Award Financial Information**

19. Budget Period Start Date	08/01/2023	- End Date	07/31/2026
20. Total Amount of Federal Funds Obligated by this Action	\$0.00		
20a. Direct Cost Amount	\$0.00		
20b. Indirect Cost Amount	\$0.00		
21. Authorized Carryover	\$0.00		
22. Offset	\$2,071,173.00		
23. Total Amount of Federal Funds Obligated this budget period	\$7,900,998.00		
24. Total Approved Cost Sharing or Matching, where applicable	\$0.00		
25. Total Federal and Non-Federal Approved this Budget Period	\$7,900,998.00		
26. Period of Performance Start Date	08/01/2019	- End Date	07/31/2026
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance	\$1,852,266,847.00		

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Karen Zionl
Grants Management Officer

30. Remarks



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000516-05-02

FAIN# NU50CK000516

Federal Award Date: 10/17/2023

Recipient Information**Recipient Name**

HEALTH RESEARCH, INC.
150 BROADWAY STE 560
-DUP4
MENANDS, NY 12204-2719
[No Phone Record]

Congressional District of Recipient

20

Payment Account Number and Type

1141402155A1

Employer Identification Number (EIN) Data

141402155

Universal Numbering System (DUNS)

002436061

Recipient's Unique Entity Identifier (UEI)

G9H6SUM59YC4

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$4,062,779.00
b. Fringe Benefits	\$1,516,020.00
c. Total Personnel Costs	\$5,578,799.00
d. Equipment	\$261,222.00
e. Supplies	\$888,538.00
f. Travel	\$112,468.00
g. Construction	\$0.00
h. Other	\$506,085.00
i. Contractual	\$796,153.00
j. TOTAL DIRECT COSTS	\$8,143,265.00
k. INDIRECT COSTS	\$1,828,906.00
l. TOTAL APPROVED BUDGET	\$9,972,171.00
m. Federal Share	\$9,972,171.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
2-939017Y	19NU50CK000516AMD4C6	CK	41.51	93.323	\$0.00	75-X-0943
0-9390F7F	19NU50CK000516C4	CK	41.51	93.323	\$0.00	75-X-0140
2-9390GKT	19NU50CK000516EDEXC5	CK	41.51	93.323	\$0.00	75-2122-0140
0-9390EWQ	19NU50CK000516C3	CK	41.51	93.323	\$0.00	75-2024-0943
0-9390EPX	19NU50CK000516CV	CK	41.51	93.323	\$0.00	75-2022-0943
1-9390GF6	19NU50CK000516PHL2C6	CK	41.51	93.323	\$0.00	75-X-0140
1-9390H08	19NU50CK000516AMD2C6	CK	41.51	93.323	\$0.00	75-X-0943
1-9390EWQ	19NU50CK000516DMODC3	CK	41.51	93.323	\$0.00	75-2024-0943
2-9390J4P	19NU50CK000516SHRPC6	CK	41.51	93.323	\$0.00	75-X-0140
2-9390JXH	19NU50CK000516LDXC6	CK	41.51	93.323	\$0.00	75-X-0140
2-9390JEN	19NU50CK000516NWSSC6	CK	41.51	93.323	\$0.00	75-X-0140



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NU50CK000516-05-02

FAIN# NU50CK000516

Federal Award Date: 10/17/2023

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH RESEARCH, INC.

6 NU50CK000516-05-02

1. Terms and Conditions - NCE

ADDITIONAL TERMS AND CONDITIONS OF AWARD

No Cost Extension: The purpose of this amendment is to approve a 24 months No Cost Extension per the request submitted by your organization dated September 21, 2023 . The budget and project period end dates have been extended from August 1, 2024 to July 31, 2026.

Annual Federal Financial Report (FFR SF-425): Annual financial reporting is required every twelve-month period. Due to the approved extension period, the final budget period has been extended and an additional annual financial report will be required. A completed FFR SF-425 covering the original final budget period of August 1, 2023 to July 31, 2026 must be submitted by October 31, 2026.

Recipients must submit all closeout reports identified in this section within 90 days of the period of performance end date. The reporting timeframe is the full period of performance. Failure to submit timely and accurate final reports may affect future funding to the organization or awards under the direction of the same Project Director/Principal Investigator (PD/PI).

Final Performance Progress and Evaluation Report (PPER): This report should include the information specified in the NOFO. At a minimum, the report will include the following:

- Statement of progress made toward the achievement of originally stated aims.
- Description of results (positive or negative) considered significant.
- List of publications resulting from the project, with plans, if any, for further publication.

All manuscripts published as a result of the work supported in part or whole by the cooperative grant must be submitted with the performance progress reports.

Final Federal Financial Report (FFR, SF-425): The FFR should only include those funds authorized and actually expended during the timeframe covered by the report. The Final FFR, SF-425 is required and must be submitted no later than 90 days after the period of performance end date.

The final report must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. Should the amount not match with the final expenditures reported to the Department of Health and Human Services' PMS, you will be required to update your reports to PMS accordingly. Remaining unobligated funds will be de-obligated and returned to the U.S. Treasury.

Electronic versions of the FFR SF-425 can be downloaded at:

<https://www.grants.gov/web/grants/forms/post-award-reporting-forms.html#sortby=1>

Equipment and Supplies - Tangible Personal Property Report (SF-428): A completed Tangible Personal Property Report SF-428 and Final Report SF-428B addendum must be submitted, along with any Supplemental Sheet SF-428S detailing all major equipment acquired or furnished under this project with a unit acquisition cost of \$5,000 or more. Electronic versions of the forms can be downloaded by visiting: <https://www.grants.gov/web/grants/forms/post-award-reporting-forms.html#sortby=1>

If no equipment was acquired under an award, a negative report is required.

The recipient must identify each item of equipment that it wishes to retain for continued use in

accordance with 45 CFR Part 75. The awarding agency may exercise its rights to require the transfer of equipment purchased under the assistance award. CDC will notify the recipient if transfer to title will be required and provide disposition instruction on all major equipment.

Equipment with a unit acquisition cost of less than \$5,000 that is no longer to be used in projects or programs currently or previously sponsored by the Federal Government may be retained, sold, or otherwise disposed of, with no further obligation to the Federal Government.

EXHIBIT H

From: ELC CAMP <campplatform@cdc.gov>
Sent: Wednesday, February 7, 2024 5:57 PM
To: [REDACTED]@health.ny.gov>
Subject: New Announcement posted in ELC Announcements

You don't often get email from campplatform@cdc.gov. [Learn why this is important](#)

ATTENTION: This email came from an external source. Do not open attachments or click on links from unknown senders or unexpected emails.



ELC Announcements — Jason Snow (CDC)

There is a new document in the Knowledge Center that relates to using Enhancing Detection and ED Expansion funds.

Please see the listing under 'Announcements' on the ELC CAMP Home page.

The resource is called: Updated Companion Clarifying Document for ELC

Enhancing Detection (ED) and Enhancing Detection Expansion (EDE) COVID-19 Funding.

[View/Comment](#) or reply to this email

You're receiving ELC CAMP emails.

To change or turn off ELC CAMP email, [log in](#) as emily.lutterloh@health.ny.gov.camp.

salesforce.com, inc. The Landmark @ One Market, Suite 300 San Francisco, CA 94105

ELC CAMP



Updated Companion Clarifying Document for ELC Enhancing Detection (ED) and Enhancing Detection Expansion (EDE) COVID-19 Funding

While ELC ED/EDE funds are already budgeted at the recipient level, below are things to consider as needs evolve. Please remember that all budget items must clearly link to an approved work plan. Please also note that unless a waiver from the Office of Financial Services (OFR) is obtained, ED/EDE funds are legislatively tied to COVID-19 and COVID-19 must be a part of the approved activities. Finally, these funds are not intended to duplicate support being provided through other forms of financial assistance. Please ensure there is ample coordination with Project Directors over grants and cooperative agreements that may have complementary work (i.e., PHEP and Crisis, Immunization, PHIG, etc.)

Clarification of Allowable Activities for the ED/EDE funds

As SARS-CoV-2/COVID-19 testing, surveillance, monitoring, and reporting becomes more integrated into the routine activities for respiratory pathogens more broadly, COVID-19 funded activities should still focus on directly benefiting COVID-19-related public health activities and improved situational awareness that may inform public health action. COVID-19-funded infrastructure and activities may integrate other pathogens and syndromes as long as COVID-19 testing or surveillance is included in the effort. For example, COVID funded laboratory, surveillance, epidemiology, and informatics personnel may work on other pathogens and syndromes, in addition to SARS-CoV-2 and COVID-19, as long as detection/assessment/reporting/visualization activities for SARS-CoV-2 and COVID-19 are included in their routine scope of work. Activities can be conducted and integrated within **broader respiratory pathogen program activities**. Examples of broad-scale work that may be appropriate to support with ED/EDE funds include (not exhaustive):

- **testing for SARS-CoV-2** alone or as part of a multi-pathogen panel
- **sequencing of SARS-CoV-2** positive specimens
- conducting sentinel or systematic respiratory pathogen focused **surveillance activities** (either laboratory based or syndrome-based approaches using case definitions of Influenza-like illness (ILI), COVID-like illness (CLI), acute respiratory illness (ARI), mortality, post-COVID conditions, and multisystem inflammatory syndrome in children (MIS-C)), including data management, analysis, visualization, and reporting
- **outbreak response** activities for respiratory illness in congregate settings that may be COVID-19-associated
- If not already supported through other awards, improving the completeness and accuracy of **immunization registries** (including for COVID-19 vaccines), or interoperability with the state's surveillance system
- Maintenance, support, and continued enhancement of **electronic integrated disease surveillance systems, public health laboratory information management system(s) (LIMS), electronic data exchange of core public health data** (e.g., electronic laboratory reports (ELR), electronic case reports (eCR), syndromic surveillance, electronic test orders and results (ETOR)), and other peripheral systems (e.g., integration engines, vocabulary services) used for the surveillance of COVID-19 and other pathogens.
- Maintenance, support, and continued enhancement of **modernized enterprise infrastructure and shared services** to ensure access to systems and data for public health action (e.g., data lakes/warehouses, master patient indices, data linkage tools, geospatial analysis)
- Development and support for internal and external **dashboards, reporting enhancements, and data modernization** that include COVID-19 data

Considerations for Utilization of Funds:

Below are items to consider that may support your approved work plans:

- Purchasing freezers, extraction equipment, testing and sequencing platforms, and other laboratory equipment, supplies, and reagents to support testing for SARS-CoV-2.
- Support for staffing with expertise in IT, data management, data visualization, communications, surveillance, epidemiology, statistical analyses, and informatics related respiratory illness and including COVID-19 and SARS-CoV-2.
- Costs related to maintenance and operations or licensing of integrated disease surveillance system or LIMS used for COVID-19 and other pathogens, including associated trainings for system administration and configuration.
- Preventative maintenance (PM) costs of already existing equipment/instruments that may be used for COVID testing. This is especially important for those assays covered under CLIA. Please remember that maintenance contracts may be set up with the manufacturer beyond warranty period for newly purchased equipment.
- Support for staffing or tools necessary for Quality Management Systems important for laboratory operations that carry out testing for SARS-CoV-2 and other respiratory pathogens.
- Enhancement of COVID and other respiratory pathogen surveillance activities and reporting.
- Regarding flexibilities related to contractual activities, consult with your jurisdiction acquisition office to learn more about your jurisdiction-specific policies. This will also require negotiation with the intended vendor.
 - Note: Service agreements that are paid up-front and have no additional costs associated at a later date can have timeframes that exceed the no-cost extension period of the ED/EDE ELC cooperative agreement period of performance which is currently July 31, 2026.

No Longer Supported

New **incentive requests**, new requests to **purchase vehicles, furniture**, and new requests for **construction** will no longer be supported. The allowance of these purchases was uniquely given during the pandemic, but they are not allowed under routine operations. This applies to recipients and subrecipients (e.g., LHDs).

EXHIBIT I



CDC Archive

This page is archived for historical purposes and is no longer being updated.



This is archived content from the CDC website. The information here may be outdated and links may no longer function. Go to CDC Home for all other recent information.

[View in CDC Archive](#)

[Go to CDC Archive Home Page](#)

CDC Announces \$2.25 Billion to Address COVID-19 Health Disparities in Communities that are at High-Risk and Underserved

Press Release

For Immediate Release: Wednesday, March 17, 2021

Contact: Media Relations
(404) 639-3286

The Centers for Disease Control and Prevention (CDC) today announced a plan to invest \$2.25 billion over two years to address Coronavirus Disease 2019 (COVID-19)-related health disparities and advance health equity among populations that are at high-risk and underserved, including racial and ethnic minority groups and people living in rural areas. This funding represents CDC's largest investment to date to support communities affected by COVID-19-related health disparities.

CDC's new National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved Communities, Including Racial and Ethnic Minority Populations and Rural Communities, will offer grants to public health departments to improve testing and contact tracing capabilities; develop innovative mitigation and prevention resources and services; improve data collection and reporting; build, leverage, and expand infrastructure support; and mobilize partners and collaborators to advance health equity and address social determinants of health as they relate to COVID-19.

"Everyone in America should have equal opportunity to be as healthy as possible," said CDC Director Rochelle P. Walensky, MD, MPH. "This investment will be monumental in anchoring equity at the center of our nation's COVID-19 response—and is a key step forward in bringing resources and focus to health inequities that have for far too long persisted in our country."

Data show that COVID-19 has disproportionately affected some populations and placed them at higher risk, including those who are medically underserved, racial and ethnic minority groups, and people living in rural communities. These groups may experience higher risk of exposure, infection, hospitalization, and mortality. In addition, evidence shows that racial and ethnic minority groups and people living in rural communities have disproportionate rates of chronic diseases that can increase the risk of becoming severely ill from COVID-19 and may also encounter barriers to testing, treatment, or vaccination.

To stop the spread of the COVID-19 virus and move toward greater health equity, CDC continues to work with populations at higher risk, underserved, and disproportionately affected to ensure resources are available to maintain and manage physical and mental health, including easy access to information, affordable testing, and medical and mental health care. For more information and community resources visit: <https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/index.html>

This initiative is funded through the Coronavirus Response and Relief Supplemental Appropriations Act, 2021, (P.L. 116-260) and is expected to award funding to up to 108 state, local, territorial, and freely associated state health departments, or their bona fide agents. CDC will be accepting applications for this initiative through April 30, 2021.

###

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 

CDC works 24/7 protecting America's health, safety and security. Whether disease start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America's most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

Last Reviewed: March 17, 2021

EXHIBIT J

**Recipient Information****1. Recipient Name**

Health Research, Inc./NYS
150 Broadway Ste 350
Health Research, Inc./New York State Department of
Health
Menands, NY 12204-2893

2. Congressional District of Recipient

20

3. Payment System Identifier (ID)

1141402155A1

4. Employer Identification Number (EIN)

141402155

5. Data Universal Numbering System (DUNS)

153695809

6. Recipient's Unique Entity Identifier**7. Project Director or Principal Investigator**

Mr. Michael A. Saglimbeni
Director, Office of Sponsored Programs
hringa@healthresearch.org
518-431-1200

8. Authorized Official

Ms. Cheryl A. Mattox
Executive Director, Health Research, Inc.
Cheryl.Mattox@healthresearch.org
518-431-1204

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Mr. John McGee
Grants Management Specialist
qsj4@cdc.gov
404-498-4348

10. Program Official Contact Information

Ms. Christine Graaf
khx2@cdc.gov
404-498-0442

Federal Award Information**11. Award Number**

1 NH75OT000075-01-00

12. Unique Federal Award Identification Number (FAIN)

NH75OT000075

13. Statutory Authority

317(K)(2) OF PHSA 42USC 247B(K)(2)

14. Federal Award Project Title

National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and
Underserved, Including Racial and Ethnic Minority Populations and Rural Communities

15. Assistance Listing Number

93.391

16. Assistance Listing Program Title

Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public
Health or Healthcare Crises

17. Award Action Type

New

18. Is the Award R&D?

No

Summary Federal Award Financial Information

19. Budget Period Start Date 06/01/2021 - **End Date** 05/31/2023

20. Total Amount of Federal Funds Obligated by this Action \$33,726,393.00

20a. Direct Cost Amount \$32,071,211.00

20b. Indirect Cost Amount \$1,655,182.00

21. Authorized Carryover \$0.00

22. Offset \$0.00

23. Total Amount of Federal Funds Obligated this budget period \$0.00

24. Total Approved Cost Sharing or Matching, where applicable \$0.00

25. Total Federal and Non-Federal Approved this Budget Period \$33,726,393.00

26. Project Period Start Date 06/01/2021 - **End Date** 05/31/2023

**27. Total Amount of the Federal Award including Approved
Cost Sharing or Matching this Project Period** Not Available

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Shirley K Byrd
Grants Management Officer

30. Remarks



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Award

Centers for Disease Control and Prevention

Award# 1 NH75OT000075-01-00

FAIN# NH75OT000075

Federal Award Date: 05/26/2021

Recipient Information**Recipient Name**

Health Research, Inc./NYS
150 Broadway Ste 350
Health Research, Inc./New York State Department of
Health
Menands, NY 12204-2893

Congressional District of Recipient

20

Payment Account Number and Type

1141402155A1

Employer Identification Number (EIN) Data

141402155

Universal Numbering System (DUNS)

153695809

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Project Grant

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$6,292,585.00
b. Fringe Benefits	\$2,464,990.00
c. Total Personnel Costs	\$8,757,575.00
d. Equipment	\$0.00
e. Supplies	\$67,800.00
f. Travel	\$836.00
g. Construction	\$0.00
h. Other	\$0.00
i. Contractual	\$23,245,000.00
j. TOTAL DIRECT COSTS	\$32,071,211.00
k. INDIRECT COSTS	\$1,655,182.00
l. TOTAL APPROVED BUDGET	\$33,726,393.00
m. Federal Share	\$33,726,393.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390H06	21NH75OT000075C5	OT	41.51	\$33,726,393.00	75-2122-0140



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 1 NH75OT000075-01-00

FAIN# NH75OT000075

Federal Award Date: 05/26/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

Health Research, Inc./NYS

1 NH75OT000075-01-00

1. Terms and Conditions

Recipient: Health Research, Inc./NYS

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-OT21-2103, entitled National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved, Including Racial and Ethnic Minority Populations and Rural Communities, and application dated April 30, 2021, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of \$33,726,393 is approved for a two year performance and budget period, which is June 1, 2021 through May 31, 2023. All future funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Component/Project Funding: The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
Base funding	\$30,704,443
State Rural Carveout	\$3,021,950

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); the Consolidated Appropriations Act and the Coronavirus Response and Relief Supplement Appropriations Act, 2021 (P.L. 116-260) and/or the American Rescue Plan of 2021 [P.L. 117-2] agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with

guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Financial Assistance Mechanism: Grant

Pre-Award Costs: Pre-award costs dating back to March 15, 2021 – and directly related to the COVID-19 outbreak response are allowable.

FUNDING RESTRICTIONS AND LIMITATIONS

Indirect Costs:

Indirect costs are approved based on the negotiated indirect cost rate agreement dated December 13, 2019, which calculates indirect costs as follows, a Provisional is approved at a rate of 19.30% of the base, which includes, direct wages and salaries including all fringe benefits. The effective dates of this indirect cost rate are from April 1, 2020 to March 31, 2023.

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
John McGee, Grants Management Specialist
Centers for Disease Control and Prevention
Global Health Services Branch
2939 Flowers Road
Atlanta, GA 30341
Email: qsj4@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services

Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

PROGRAM OR FUNDING SPECIFIC CLOSEOUT REQUIREMENTS

The final programmatic report format required is the following.

Final Performance Progress and Evaluation Report: This report should include the information specified in the NOFO and is submitted 90 days following the end of the period of performance via www.grantsolutions.gov. At a minimum, the report will include the following:

- Statement of progress made toward the achievement of originally stated aims.
- Description of results (positive or negative) considered significant.

- List of publications resulting from the project, with plans, if any, for further publication.

Additional guidance may be provided by the GMS and found at:

<https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html>

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

EXHIBIT K



Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-01

FAIN# NH75OT000075

Federal Award Date: 03/17/2023

Recipient Information**1. Recipient Name**

HEALTH RESEARCH, INC.
150 Broadway STE 280
Riverview Center
Health Research, Inc./New York State Department of Health
Menands, NY 12204-2732

2. Congressional District of Recipient

20

3. Payment System Identifier (ID)

1141402155A1

4. Employer Identification Number (EIN)

141402155

5. Data Universal Numbering System (DUNS)

153695809

6. Recipient's Unique Entity Identifier (UEI)

WJ37AD42G8A5

7. Project Director or Principal Investigator

Mr. Michael A. Saglimbeni
Director, Office of Sponsored Programs
hringa@healthresearch.org
518-431-1200

8. Authorized Official

Ms. Cheryl A. Mattox
Executive Director, Health Research, Inc.
hringa@healthresearch.org
518-431-1204

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Jennifer Allen
GMS
trd3@cdc.gov
404-498-0976

10. Program Official Contact Information

Natasha Dixon
Program Officer
CSTLTS
swx3@cdc.gov
4044980753

Federal Award Information**11. Award Number**

6 NH75OT000075-01-01

12. Unique Federal Award Identification Number (FAIN)

NH75OT000075

13. Statutory Authority

317(K)(2) OF PHSA 42USC 247B(K)(2)

14. Federal Award Project Title

National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved, Including Racial and Ethnic Minority Populations and Rural Communities

15. Assistance Listing Number

93.391

16. Assistance Listing Program Title

Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises

17. Award Action Type

No Cost Extension

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 06/01/2021 - **End Date** 05/31/2024**20. Total Amount of Federal Funds Obligated by this Action** \$0.00

20a. Direct Cost Amount (\$348,442.00)

20b. Indirect Cost Amount \$348,442.00

21. Authorized Carryover \$0.00**22. Offset** \$0.00**23. Total Amount of Federal Funds Obligated this budget period** \$33,726,393.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$33,726,393.00**26. Period of Performance Start Date** 06/01/2021 - **End Date** 05/31/2024**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance** \$33,726,393.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Ester Edward
Grants Management Officer

30. Remarks



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-01

FAIN# NH75OT000075

Federal Award Date: 03/17/2023

Recipient Information**Recipient Name**

HEALTH RESEARCH, INC.

150 Broadway STE 280

Riverview Center

Health Research, Inc./New York State Department of
Health

Menands, NY 12204-2732

Congressional District of Recipient

20

Payment Account Number and Type

1141402155A1

Employer Identification Number (EIN) Data

141402155

Universal Numbering System (DUNS)

153695809

Recipient's Unique Entity Identifier (UEI)

WJ37AD42G8A5

31. Assistance Type

Project Grant

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$7,693,164.00
b. Fringe Benefits	\$2,908,016.00
c. Total Personnel Costs	\$10,601,180.00
d. Equipment	\$0.00
e. Supplies	\$88,815.00
f. Travel	\$17,855.00
g. Construction	\$0.00
h. Other	\$80,612.00
i. Contractual	\$20,934,307.00
j. TOTAL DIRECT COSTS	\$31,722,769.00
k. INDIRECT COSTS	\$2,003,624.00
l. TOTAL APPROVED BUDGET	\$33,726,393.00
m. Federal Share	\$33,726,393.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390H06	21NH75OT000075C5	OT	41.51	93.391	\$0.00	75-2122-0140



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-01

FAIN# NH75OT000075

Federal Award Date: 03/17/2023

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH RESEARCH, INC.

6 NH75OT000075-01-01

1. Terms & Conditions - NCE

No Cost Extension: The purpose of this amendment is to approve a **12-month** No Cost Extension per the request submitted by your organization dated **February 28, 2023**. **The budget and project period end dates have been extended to May 31, 2024.**

Annual Federal Financial Report (FFR SF-425): Annual financial reporting is required every twelve-month period. Due to the approved extension period, the final budget period has been extended and an additional annual financial report will be required. **A completed FFR SF-425 covering the budget period of June 1, 2022 to May 31, 2023 must be submitted by August 31, 2023.**

Recipients must submit all closeout reports identified in this section within 90 days of the period of performance end date. The reporting timeframe is the full period of performance. Failure to submit timely and accurate final reports may affect future funding to the organization or awards under the direction of the same Project Director/Principal Investigator (PD/PI).

Final Performance Progress and Evaluation Report: This report should include the information specified in the NOFO and is submitted 90 days following the end of the period of performance via www.grantsolutions.gov. At a minimum, the report will include the following:

1. Statement of progress made toward the achievement of originally stated aims.
2. Description of results (positive or negative) considered significant.
3. List of publications resulting from the project, with plans, if any, for further publication.

Additional guidance may be provided by the GMS and found at:
<https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html>

Final Federal Financial Report (FFR, SF-425): The FFR should only include those funds authorized and actually expended during the timeframe covered by the report. The Final FFR, SF-425 is required and must be submitted no later than 90 days after the period of performance end date.

The final report must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. Should the amount not match with the final expenditures reported to the Department of Health and Human Services' PMS, you will be required to update your reports to PMS accordingly. Remaining unobligated funds will be de-obligated and returned to the U.S. Treasury.

Equipment and Supplies - Tangible Personal Property Report (SF-428): A completed Tangible Personal Property Report SF-428 and Final Report SF-428B addendum must be submitted, along with any Supplemental Sheet SF-428S detailing all major equipment acquired or furnished under this project with a unit acquisition cost of \$5,000 or more. Electronic versions of the forms can be downloaded by visiting:
<https://www.grants.gov/web/grants/forms/post-award-reporting-forms.html#sortby=1>

If no equipment was acquired under an award, a negative report is required.

The recipient must identify each item of equipment that it wishes to retain for continued use in accordance with 45 CFR Part 75. The awarding agency may exercise its rights to require the transfer of equipment purchased under the assistance award. CDC will notify the recipient if

transfer to title will be required and provide disposition instruction on all major equipment.

Equipment with a unit acquisition cost of less than \$5,000 that is no longer to be used in projects or programs currently or previously sponsored by the Federal Government may be retained, sold, or otherwise disposed of, with no further obligation to the Federal Government.

Please be advised that the recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to their cooperative agreement are allowable, allocable, necessary and reasonable.

All other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

PLEASE REFERENCE THE NOFO AND AWARD NUMBER ON ALL CORRESPONDENCE

EXHIBIT L



Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-02

FAIN# NH75OT000075

Federal Award Date: 03/27/2023

Recipient Information**1. Recipient Name**

HEALTH RESEARCH, INC.
150 Broadway STE 280
Riverview Center
Health Research, Inc./New York State Department of Health
Menands, NY 12204-2732

2. Congressional District of Recipient

20

3. Payment System Identifier (ID)

1141402155A1

4. Employer Identification Number (EIN)

141402155

5. Data Universal Numbering System (DUNS)

153695809

6. Recipient's Unique Entity Identifier (UEI)

WJ37AD42G8A5

7. Project Director or Principal Investigator

Mr. Michael A. Saglimbeni
Director, Office of Sponsored Programs
hringa@healthresearch.org
518-431-1200

8. Authorized Official

Ms. Cheryl A. Mattox
Executive Director, Health Research, Inc.
hringa@healthresearch.org
518-431-1204

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Jennifer Allen
GMS
trd3@cdc.gov
404-498-0976

10. Program Official Contact Information

Natasha Dixon
Program Officer
CSTLTS
swx3@cdc.gov
4044980753

Federal Award Information**11. Award Number**

6 NH75OT000075-01-02

12. Unique Federal Award Identification Number (FAIN)

NH75OT000075

13. Statutory Authority

317(K)(2) OF PHSA 42USC 247B(K)(2)

14. Federal Award Project Title

National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved, Including Racial and Ethnic Minority Populations and Rural Communities

15. Assistance Listing Number

93.391

16. Assistance Listing Program Title

Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises

17. Award Action Type

Administrative Action

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 06/01/2021 - **End Date** 05/31/2024**20. Total Amount of Federal Funds Obligated by this Action** \$0.00

20a. Direct Cost Amount \$669,321.00

20b. Indirect Cost Amount (\$669,321.00)

21. Authorized Carryover \$0.00**22. Offset** \$0.00**23. Total Amount of Federal Funds Obligated this budget period** \$33,726,393.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$33,726,393.00**26. Period of Performance Start Date** 06/01/2021 - **End Date** 05/31/2024**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance** \$33,726,393.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Ester Edward
Grants Management Officer

30. Remarks

**Recipient Information****Recipient Name**

HEALTH RESEARCH, INC.

150 Broadway STE 280

Riverview Center

Health Research, Inc./New York State Department of
Health

Menands, NY 12204-2732

Congressional District of Recipient

20

Payment Account Number and Type

1141402155A1

Employer Identification Number (EIN) Data

141402155

Universal Numbering System (DUNS)

153695809

Recipient's Unique Entity Identifier (UEI)

WJ37AD42G8A5

31. Assistance Type

Project Grant

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$5,040,538.00
b. Fringe Benefits	\$2,019,262.00
c. Total Personnel Costs	\$7,059,800.00
d. Equipment	\$0.00
e. Supplies	\$83,331.00
f. Travel	\$37,657.00
g. Construction	\$0.00
h. Other	\$1,966,302.00
i. Contractual	\$23,245,000.00
j. TOTAL DIRECT COSTS	\$32,392,090.00
k. INDIRECT COSTS	\$1,334,303.00
l. TOTAL APPROVED BUDGET	\$33,726,393.00
m. Federal Share	\$33,726,393.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390H06	21NH75OT000075C5	OT	41.51	93.391	\$0.00	75-2122-0140



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-02

FAIN# NH75OT000075

Federal Award Date: 03/27/2023

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH RESEARCH, INC.

6 NH75OT000075-01-02

1. Terms & Conditions

REVISED AWARD INFORMATION

Administrative Correction: The purpose of this Notice of Award is to correct the Approved Budget allocations.

No action is required from the recipient.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT M



Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-03

FAIN# NH75OT000075

Federal Award Date: 02/28/2024

Recipient Information**1. Recipient Name**

HEALTH RESEARCH, INC.
150 Broadway STE 280
Riverview Center
Health Research, Inc./New York State Department of
Health
Menands, NY 12204-2732

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1141402155A1

4. Employer Identification Number (EIN)

141402155

5. Data Universal Numbering System (DUNS)

153695809

6. Recipient's Unique Entity Identifier (UEI)

WJ37AD42G8A5

7. Project Director or Principal Investigator

Dr. Kirsten Siegenthaler Ph.D
Principal Investigator
kirsten.siegenthaler@health.ny.gov
(518)473-7016

8. Authorized Official

Ms. Cheryl A. Mattox
Executive Director, Health Research, Inc.
hringa@healthresearch.org
518-431-1200

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Charlena Gatlin
Internal Reviewer
tie3@cdc.gov
678-475-4966

10. Program Official Contact Information

Natasha Dixon
Program Officer
CSTLTS
swx3@cdc.gov
4044980753

Federal Award Information**11. Award Number**

6 NH75OT000075-01-03

12. Unique Federal Award Identification Number (FAIN)

NH75OT000075

13. Statutory Authority

317(K)(2) OF PHSA 42USC 247B(K)(2)

14. Federal Award Project Title

National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and
Underserved, Including Racial and Ethnic Minority Populations and Rural Communities

15. Assistance Listing Number

93.391

16. Assistance Listing Program Title

Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public
Health or Healthcare Crises

17. Award Action Type

No Cost Extension

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 06/01/2021 - **End Date** 05/31/2026**20. Total Amount of Federal Funds Obligated by this Action** \$0.00

20a. Direct Cost Amount \$0.00

20b. Indirect Cost Amount \$0.00

21. Authorized Carryover \$0.00**22. Offset** \$0.00**23. Total Amount of Federal Funds Obligated this budget period** \$33,726,393.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$33,726,393.00**26. Period of Performance Start Date** 06/01/2021 - **End Date** 05/31/2026**27. Total Amount of the Federal Award including Approved
Cost Sharing or Matching this Period of Performance** \$33,726,393.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Ms. Ester Edward
Grants Management Officer

30. Remarks



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-03

FAIN# NH75OT000075

Federal Award Date: 02/28/2024

Recipient Information**Recipient Name**

HEALTH RESEARCH, INC.

150 Broadway STE 280

Riverview Center

Health Research, Inc./New York State Department of
Health

Menands, NY 12204-2732

Congressional District of Recipient

20

Payment Account Number and Type

1141402155A1

Employer Identification Number (EIN) Data

141402155

Universal Numbering System (DUNS)

153695809

Recipient's Unique Entity Identifier (UEI)

WJ37AD42G8A5

31. Assistance Type

Project Grant

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$5,040,538.00
b. Fringe Benefits	\$2,019,262.00
c. Total Personnel Costs	\$7,059,800.00
d. Equipment	\$0.00
e. Supplies	\$83,331.00
f. Travel	\$37,657.00
g. Construction	\$0.00
h. Other	\$1,966,302.00
i. Contractual	\$23,245,000.00
j. TOTAL DIRECT COSTS	\$32,392,090.00
k. INDIRECT COSTS	\$1,334,303.00
l. TOTAL APPROVED BUDGET	\$33,726,393.00
m. Federal Share	\$33,726,393.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390H06	21NH75OT000075C5	OT	41.51	93.391	\$0.00	75-2122-0140



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-03

FAIN# NH75OT000075

Federal Award Date: 02/28/2024

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH RESEARCH, INC.

6 NH75OT000075-01-03

1. Terms and Conditions

ADDITIONAL TERMS AND CONDITIONS OF AWARD

The General Terms and Conditions for [non-research](#) grants and cooperative agreements have been updated, effective January 23, 2024, to reflect current regulations and requirements for federal financial assistance.

No Cost Extension: The purpose of this amendment is to approve a 24 month No Cost Extension per the request submitted by your organization dated January 30, 2024 . The budget and project period end dates have been extended from May 31, 2024 to May 31, 2026.

Annual Federal Financial Report (FFR SF-425): Annual financial reporting is required every twelve-month period. Based on the approved no-cost extension, an additional annual financial report will be required. A completed FFR SF-425 covering the budget period of June 1, 2023 to May 31, 2024 must be submitted by August 31, 2024.

Closeout Requirements: Recipients must submit all closeout reports within 120 days of the period of performance end date. Standard closeout reporting requirements are identified in the *General Terms and Conditions*, which are published on the CDC website at <https://www.cdc.gov/grants/federal-regulations-policies/index.html>

EXHIBIT N



Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-04

FAIN# NH75OT000075

Federal Award Date: 03/24/2025

Recipient Information**1. Recipient Name**

HEALTH RESEARCH, INC.
150 Broadway STE 280
Riverview Center
Health Research, Inc./New York State Department of Health
Menands, NY 12204-2732

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1141402155A1

4. Employer Identification Number (EIN)

141402155

5. Data Universal Numbering System (DUNS)

153695809

6. Recipient's Unique Entity Identifier (UEI)

WJ37AD42G8A5

7. Project Director or Principal Investigator

Dr. Kirsten Siegenthaler Ph.D
Principal Investigator
kirsten.siegenthaler@health.ny.gov
(518)473-7016

8. Authorized Official

Ms. Cheryl A. Mattox
Executive Director, Health Research, Inc.
hringa@healthresearch.org
518-431-1200

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Ms. Ester Edward
Grants Management Officer
ece9@cdc.gov
(770) 488-2852

10. Program Official Contact Information

Natasha Dixon
Program Officer
CSTLTS
swx3@cdc.gov
4044980753

Federal Award Information**11. Award Number**

6 NH75OT000075-01-04

12. Unique Federal Award Identification Number (FAIN)

NH75OT000075

13. Statutory Authority

317(K)(2) OF PHSA 42USC 247B(K)(2)

14. Federal Award Project Title

National Initiative to Address COVID-19 Health Disparities Among Populations at High-Risk and Underserved, Including Racial and Ethnic Minority Populations and Rural Communities

15. Assistance Listing Number

93.391

16. Assistance Listing Program Title

Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises

17. Award Action Type

Terminate

18. Is the Award R&D?

No

Summary Federal Award Financial Information

19. Budget Period Start Date	06/01/2021	- End Date	03/24/2025
20. Total Amount of Federal Funds Obligated by this Action	\$0.00		
20a. Direct Cost Amount	\$0.00		
20b. Indirect Cost Amount	\$0.00		
21. Authorized Carryover	\$0.00		
22. Offset	\$0.00		
23. Total Amount of Federal Funds Obligated this budget period	\$33,726,393.00		
24. Total Approved Cost Sharing or Matching, where applicable	\$0.00		
25. Total Federal and Non-Federal Approved this Budget Period	\$33,726,393.00		
26. Period of Performance Start Date	06/01/2021	- End Date	03/24/2025
27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance	\$33,726,393.00		

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Mrs. Erica Stewart
Team Lead, Grants Management Officer

30. Remarks

Department Authority

**Recipient Information****Recipient Name**

HEALTH RESEARCH, INC.

150 Broadway STE 280

Riverview Center

Health Research, Inc./New York State Department of
Health

Menands, NY 12204-2732

Congressional District of Recipient

20

Payment Account Number and Type

1141402155A1

Employer Identification Number (EIN) Data

141402155

Universal Numbering System (DUNS)

153695809

Recipient's Unique Entity Identifier (UEI)

WJ37AD42G8A5

31. Assistance Type

Project Grant

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$5,040,538.00
b. Fringe Benefits	\$2,019,262.00
c. Total Personnel Costs	\$7,059,800.00
d. Equipment	\$0.00
e. Supplies	\$83,331.00
f. Travel	\$37,657.00
g. Construction	\$0.00
h. Other	\$1,966,302.00
i. Contractual	\$23,245,000.00
j. TOTAL DIRECT COSTS	\$32,392,090.00
k. INDIRECT COSTS	\$1,334,303.00
l. TOTAL APPROVED BUDGET	\$33,726,393.00
m. Federal Share	\$33,726,393.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	ASSISTANCE LISTING	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390H06	21NH75OT000075C5	OT	41.51	93.391	\$0.00	75-2122-0140



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH75OT000075-01-04

FAIN# NH75OT000075

Federal Award Date: 03/24/2025

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH RESEARCH, INC.

6 NH75OT000075-01-04

1. Terms and conditions

TERMS AND CONDITIONS OF AWARD

Termination: The purpose of this amendment is to terminate this award which is funded by COVID-19 supplemental appropriations. The termination of this award is for cause. HHS regulations permit termination if “the non-Federal entity fails to comply with the terms and conditions of the award”, or separately, “for cause.” The end of the pandemic provides cause to terminate COVID-related grants and cooperative agreements. These grants and cooperative agreements were issued for a limited purpose: to ameliorate the effects of the pandemic. Now that the pandemic is over, the grants and cooperative agreements are no longer necessary as their limited purpose has run out. Termination of this award is effective as of the date set out in your Notice of Award.

No additional activities can be conducted, and no additional costs may be incurred. Unobligated award balances will be de-obligated by CDC.

Closeout: In order to facilitate an orderly closeout, we are requesting that you submit all closeout reports identified below within thirty (30) days of the date of this NoA. Submit the documentation as a “Grant Closeout” amendment in GrantSolutions. The reporting timeframe is the full period of performance. Please note, if you fail to submit timely and accurate reports, CDC may also pursue other enforcement actions per 45 CFR Part 75.371.

Final Performance/Progress Report: This report should include the information specified in the Notice of Funding Opportunity (NOFO). At a minimum, the report will include the following:

- Statement of progress made toward the achievement of originally stated aims.
- Description of results (positive or negative) considered significant.
- List of publications resulting from the project, with plans, if any, for further publication.

Final Federal Financial Report (FFR, SF-425): The FFR should only include those funds authorized and expended during the timeframe covered by the report. The final report must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. Should the amount not match with the final expenditures reported to the Payment Management System (PMS), you will be required to update your reports to PMS accordingly.

Equipment and Supplies - Tangible Personal Property Report (SF-428): A completed SF-428 detailing all major equipment acquired with a unit acquisition cost of \$10,000 or more. If no equipment was acquired under the award, a negative report is required

EXHIBIT O

1. DATE ISSUED MM/DD/YYYY 06/05/2020	1a. SUPERSEDES AWARD NOTICE dated 06/05/2020 except that any additions or restrictions previously imposed remain in effect unless specifically rescinded
2. CFDA NO. 93.268 - Immunization Cooperative Agreements	
3. ASSISTANCE TYPE Cooperative Agreement	
4. GRANT NO. 6 NH23IP922625-01-04 Formerly	5. TYPE OF AWARD Demonstration
4a. FAIN NH23IP922625	5a. ACTION TYPE Post Award Amendment
6. PROJECT PERIOD MM/DD/YYYY From 07/01/2019 Through 06/30/2024	
7. BUDGET PERIOD MM/DD/YYYY From 07/01/2019 Through 06/30/2020	
8. TITLE OF PROJECT (OR PROGRAM) CDC-RFA-IP19-1901 Immunization and Vaccines for Children	

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C.
Sections 247b, 247b(k)(2) and 247c), as amended.

9a. GRANTEE NAME AND ADDRESS HEALTH, NEW YORK DEPARTMENT OF Empire State Plaza NY State Dept. Of Health Albany, NY 12237-0001	9b. GRANTEE PROJECT DIRECTOR Dr. Elizabeth Rausch-Phung ESP Corning Tower Building Albany, NY 12237-0001 Phone: (518) 473-4437
10a. GRANTEE AUTHORIZING OFFICIAL Mr. Andrew T. Ruby ESP Corning Tower Building NY State Dept. Of Health Albany, NY 12237-0001	10b. FEDERAL PROJECT OFFICER Candelaria Rijo 1600 Clifton Rd Atlanta, GA 30333 Phone: 404-639-8526

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)		12. AWARD COMPUTATION	
I Financial Assistance from the Federal Awarding Agency Only		a. Amount of Federal Financial Assistance (from item 11m) 18,583,796.00	
II Total project costs including grant funds and all other financial participation I		b. Less Unobligated Balance From Prior Budget Periods 0.00	
a. Salaries and WageS 3,373,945.00		c. Less Cumulative Prior Award(s) This Budget Period 13,305,828.00	
b. Fringe Benefits 1,914,775.00		d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION 5,277,968.00	
c. Total Personnel Costs 5,288,720.00		13. Total Federal Funds Awarded to Date for Project Period 18,583,796.00	
d. Equipment 8,000.00		14. RECOMMENDED FUTURE SUPPORT (Subject to the availability of funds and satisfactory progress of the project):	
e. Supplies 64,804.00		YEAR TOTAL DIRECT COSTS YEAR TOTAL DIRECT COSTS	
f. Travel 94,917.00		a. 2 b. 3 c. 4 d. 5 e. 6 f. 7	
g. Construction 0.00		15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:	
h. Other 5,643,868.00		a. DEDUCTION	
i. Contractual 6,368,814.00		b. ADDITIONAL COSTS	
j. TOTAL DIRECT COSTS → 17,469,123.00		c. MATCHING	
k. INDIRECT COSTS 1,114,673.00		d. OTHER RESEARCH (Add / Deduct Option)	
l. TOTAL APPROVED BUDGET 18,583,796.00		e. OTHER (See REMARKS)	
m. Federal Share 18,583,796.00		16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:	
n. Non-Federal Share 0.00		a. The grant program legislation	
		b. The grant program regulations.	
		c. This award notice including terms and conditions, if any, noted below under REMARKS.	
		d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.	
		In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.	

REMARKS (Other Terms and Conditions Attached -

☒ Yes

☐ No)

GRANTS MANAGEMENT OFFICIAL:

Brownie Anderson-Rana, Grants Management Officer
2939 Flowers Road
Mailstop TV2
Atlanta, GA 30341-5509
Phone: 770-488-2771

17.OBJ CLASS 41.51	18a. VENDOR CODE 1146013200R9	18b. EIN 146013200	19. DUNS 806781340	20. CONG. DIST. 20
FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	AMT ACTION FIN ASST	APPROPRIATION
21. a. 0-9390EWQ	b. 19NH23IP922625C3	c. IP	d. \$5,277,968.00	e. 75-2024-0943
22. a.	b.	c.	d.	e.
23. a.	b.	c.	d.	e.

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 06/05/2020
GRANT NO. 6 NH23IP922625-01-04	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 06/05/2020
GRANT NO. 6 NH23IP922625-01-04	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
07/01/2019	06/30/2020	Annual	09/28/2020

AWARD ATTACHMENTS

HEALTH, NEW YORK DEPARTMENT OF

6 NH23IP922625-01-04

1. CARES TERMS AND CONDITIONS

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19- 1901, entitled Immunization and Vaccines for Children, which is hereby made a part of this Non- research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Funding: Additional funding in the amount \$ 5,277,968 is approved for the Year 01 budget period, which is July 1, 2019 through June 30, 2020

COVID-19: P.L. 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Activities

Recipients have **13 months** from the date of this NoA to expend all funds awarded herein

Budget/Workplan Revision Requirement: Within 30 days of this NoA, the recipient must submit a revised budget with a narrative justification outlining response activities. Failure to submit the required information in a timely manner may adversely affect the future funding of the project. If the information cannot be provided by the due date, you are required to contact your Project Officer and Grant Management Specialist. The revised budget must be uploaded in GrantSolutions as an amendment to allow issuance of a revised NoA.

Pre-Award Costs: Pre-award costs dating back to January 20, 2020 – when CDC first activated its Emergency Operations Center (EOC) – and directly related to the COVID-19 outbreak response are allowable.

Indirect Costs: Indirect cost will be approved based on current approved negotiated indirect cost rate agreement.

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Additional Term and Condition:

A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect

SARS– CoV–2 or to diagnose a possible case of COVID–19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- ***All unallowable costs cited in CDC-RFA-IP19-1901 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.***

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Freda Johnson, Grants Management

Specialist Office of Grants Services (OGS)
Office of Financial Resources (OFR)
Office of the Chief Operating Officer (OCOO)
Centers for Disease Control and Prevention
(CDC) Wve2@cdc.gov | 404-488-3107 office

AND

U.S. Department of Health and Human Services Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator 330 Independence Avenue,
SW Cohen Building, Room 5527 Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or

Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1- 800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhtips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT P

1. DATE ISSUED MM/DD/YYYY 09/23/2020 1a. SUPERSEDES AWARD NOTICE dated 06/26/2021 PageID #: 2625

except that any additions or restrictions previously imposed remain in effect unless specifically rescinded

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC Office of Financial Resources

2939 Brandywine Road
Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

3. ASSISTANCE TYPE Cooperative Agreement

4. GRANT NO. 6 NH23IP922625-02-01

Formerly

5. TYPE OF AWARD

Demonstration

4a. FAIN NH23IP922625

5a. ACTION TYPE Post Award Amendment

6. PROJECT PERIOD MM/DD/YYYY

From 07/01/2019

Through

MM/DD/YYYY

06/30/2024

7. BUDGET PERIOD MM/DD/YYYY

From 07/01/2020

Through

MM/DD/YYYY

06/30/2021

8. TITLE OF PROJECT (OR PROGRAM)

CDC-RFA-IP19-1901 Immunization and Vaccines for Children

9a. GRANTEE NAME AND ADDRESS

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001

9b. GRANTEE PROJECT DIRECTOR

Dr. Elizabeth Rausch-Phung
ESP Corning Tower Building
Albany, NY 12237-0001
Phone: (518) 473-4437

10a. GRANTEE AUTHORIZING OFFICIAL

Mr. Andrew T. Ruby
ESP Corning Tower Building
NY State Dept. Of Health
Albany, NY 12237-0001

10b. FEDERAL PROJECT OFFICER

Candelaria Rijo
1600 Clifton Rd
Atlanta, GA 30333
Phone: 404-639-8526

ALL AMOUNTS ARE SHOWN IN USD

11. APPROVED BUDGET (Excludes Direct Assistance)

I Financial Assistance from the Federal Awarding Agency Only

II Total project costs including grant funds and all other financial participation

I

a. Salaries and WageS	4,033,723.00
b. Fringe Benefits	2,384,736.00
c. Total Personnel Costs	6,418,459.00
d. Equipment	8,000.00
e. Supplies	257,000.00
f. Travel	102,535.00
g. Construction	0.00
h. Other	449,143.00
i. Contractual	11,863,307.00
j. TOTAL DIRECT COSTS	19,098,444.00
k. INDIRECT COSTS	834,399.00
l. TOTAL APPROVED BUDGET	19,932,843.00
m. Federal Share	19,932,843.00
n. Non-Federal Share	0.00

12. AWARD COMPUTATION

a. Amount of Federal Financial Assistance (from item 11m)	19,932,843.00
b. Less Unobligated Balance From Prior Budget Periods	0.00
c. Less Cumulative Prior Award(s) This Budget Period	12,097,245.00
d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION	7,835,598.00
13. Total Federal Funds Awarded to Date for Project Period	38,516,639.00

14. RECOMMENDED FUTURE SUPPORT

(Subject to the availability of funds and satisfactory progress of the project):

YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL DIRECT COSTS
a. 3		d. 6	
b. 4		e. 7	
c. 5		f. 8	

15. PROGRAM INCOME SHALL BE USED IN ACCORD WITH ONE OF THE FOLLOWING ALTERNATIVES:

- a. DEDUCTION
- b. ADDITIONAL COSTS
- c. MATCHING
- d. OTHER RESEARCH (Add / Deduct Option)
- e. OTHER (See REMARKS)

b

16. THIS AWARD IS BASED ON AN APPLICATION SUBMITTED TO, AND AS APPROVED BY, THE FEDERAL AWARDDING AGENCY ON THE ABOVE TITLED PROJECT AND IS SUBJECT TO THE TERMS AND CONDITIONS INCORPORATED EITHER DIRECTLY OR BY REFERENCE IN THE FOLLOWING:

- a. The grant program legislation
- b. The grant program regulations,
- c. This award notice including terms and conditions, if any, noted below under REMARKS,
- d. Federal administrative requirements, cost principles and audit requirements applicable to this grant.

In the event there are conflicting or otherwise inconsistent policies applicable to the grant, the above order of precedence shall prevail. Acceptance of the grant terms and conditions is acknowledged by the grantee when funds are drawn or otherwise obtained from the grant payment system.

REMARKS (Other Terms and Conditions Attached -

☒ Yes☐ No

Supplemental Funding: Financial Assistance in the amount of \$7,835,598

GRANTS MANAGEMENT OFFICIAL:

Brownie Anderson-Rana, Grants Management Officer
2939 Flowers Road
Mailstop TV2
Atlanta, GA 30341-5509
Phone: 770-488-2771

17.OBJ CLASS	41.51	18a. VENDOR CODE	1146013200R9	18b. EIN	146013200	19. DUNS	806781340	20. CONG. DIST.	20
FY-ACCOUNT NO.		DOCUMENT NO.		ADMINISTRATIVE CODE		AMT ACTION FIN ASST		APPROPRIATION	
21. a.	0-9390BKG	b.	19NH23IP922625	c.	IP	d.	\$294,723.00	e.	75-75-X-0512-009
22. a.	0-9390FG3	b.	20NH23IP922625C3	c.	IP	d.	\$7,540,875.00	e.	75-2024-0943
23. a.		b.		c.		d.		e.	

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3	DATE ISSUED 09/23/2020
GRANT NO. 6 NH23IP922625-02-01	

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3	DATE ISSUED 09/23/2020
GRANT NO. 6 NH23IP922625-02-01	

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
07/01/2019	06/30/2020	Annual	09/28/2020
07/01/2020	06/30/2021	Annual	09/28/2021

AWARD ATTACHMENTS

HEALTH, NEW YORK DEPARTMENT OF

6 NH23IP922625-02-01

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at

<https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19-1901, entitled, *Immunization and Vaccines for Children*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount **\$7,835,598** is approved for the Year 02 budget period, which is July1, 2020 through June 30, 2021.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
CORE	\$294,723
COVID-19 CARES	\$7,540,845

Recipients have until July 5, 2021 to expend all COVID-19 funds awarded herein

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data->

[reporting-guidance.pdf](#).

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-CK19-1904 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 and VFC Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification and workplan within 30 days after the receipt of this Notice of Award. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date. **A separate narrative and workplan must be submitted in accordance with the COVID-19 guidance and must also be uploaded in GMM as an amendment with a SF424A.**

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information

System (FAPIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Wayne Woods, Grants Management Officer
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, M/S E-15
Atlanta, GA 30341
Email: kuv1@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures,
Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line)
or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1- 800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the “P Account”. Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Component: CORE

Document Number: 19NH23IP922625

Component: COVID-19

Document Number: 20NH23IP922625C3

CDC Staff Contacts

Grants Management Specialist:

Wayne Woods, Grants Management Specialist (GMS)
Centers for Disease Control and Prevention
Branch 1
2920 Brandywine Road, M/S E-15
Atlanta, GA 30341
Telephone: 770-488-2948
Email: kuv1@cdc.gov

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT Q



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-02

FAIN# NH23IP922625

Federal Award Date: 12/16/2020

Recipient Information**1. Recipient Name**

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
[NoPhoneRecord]

2. Congressional District of Recipient

20

3. Payment System Identifier (ID)

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier**7. Project Director or Principal Investigator**

Dr. Elizabeth Rausch-Phung
Director, Bureau of Immunization
elizabeth.rausch-phung@health.ny.gov
(518) 473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

Candelaria Rijo
cqr5@cdc.gov
404-639-8526

Federal Award Information**11. Award Number**

6 NH23IP922625-02-02

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended

14. Federal Award Project Title

CDC-RFA-IP19-1901 Immunization and Vaccines for Children

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2020 - **End Date** 06/30/2021**20. Total Amount of Federal Funds Obligated by this Action** \$5,277,968.00

20a. Direct Cost Amount \$5,277,968.00

20b. Indirect Cost Amount \$0.00

21. Authorized Carryover \$0.00**22. Offset** \$0.00**23. Total Amount of Federal Funds Obligated this budget period** \$19,932,843.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$25,210,811.00**26. Project Period Start Date** 07/01/2019 - **End Date** 06/30/2024**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period** \$43,794,607.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Freda Johnson

30. Remarks

Supplemental Funding in the Amount of \$5,277,968

**Recipient Information****Recipient Name**

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
[NoPhoneRecord]

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Cooperative Agreement

32. Type of Award

Demonstration

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$4,033,723.00
b. Fringe Benefits	\$2,384,736.00
c. Total Personnel Costs	\$6,418,459.00
d. Equipment	\$8,000.00
e. Supplies	\$257,000.00
f. Travel	\$102,535.00
g. Construction	\$0.00
h. Other	\$449,143.00
i. Contractual	\$17,141,275.00
j. TOTAL DIRECT COSTS	\$24,376,412.00
k. INDIRECT COSTS	\$834,399.00
l. TOTAL APPROVED BUDGET	\$25,210,811.00
m. Federal Share	\$25,210,811.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390FG3	20NH23IP922625C3	IP	41.51	\$5,277,968.00	75-2024-0943

**DEPARTMENT OF HEALTH AND HUMAN SERVICES** Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-02

FAIN# NH23IP922625

Federal Award Date: 12/16/2020

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-02

FAIN# NH23IP922625

Federal Award Date: 12/16/2020

35. Terms And Conditions

Federal Financial Report Cycle			
Reporting Period Start Date	Reporting Period End Date	Reporting Type	Reporting Period Due Date
07/01/2019	06/30/2020	Annual	09/28/2020
07/01/2020	06/30/2021	Annual	09/28/2021

AWARD ATTACHMENTS

HEALTH, NEW YORK DEPARTMENT OF

6 NH23IP922625-02-02

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19-1901, entitled, *Immunization and Vaccines for Children*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount \$5,277,968 is approved for the Year 02 budget period, which is July 1, 2020 through June 30, 2021.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
COVID-19	\$5,277,968

Recipients have until June 30, 2022 to expend all COVID-19 funds awarded in Year 2

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); and/or the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting guidance is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what

is encompassed by this requirement.

This award is contingent upon agreement by the recipient to comply with existing and future guidance from the HHS Secretary regarding control of the spread of COVID-19. In addition, recipient is expected to flow down these terms to any subaward, to the extent applicable to activities set out in such subaward.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-IP19-1901 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

ADMINISTRATIVE REQUIREMENTS

The recipient must respond to the comments in the technical review and/or OGS Budget Comments in accordance with the recommendations provided in GrantSolutions as a Grant Note within 45 days of receipt of the Notice of Award. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIS):

Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services

Wayne Woods, Grants Management Specialist (GMS)
Centers for Disease Control and Prevention
Branch 1
2920 Brandywine Road, M/S E-15
Atlanta, GA 30341
Telephone: 770-488-2948
Email: kuv1@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures,
Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line)
or Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1- 800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhs tips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT R



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-03

FAIN# NH23IP922625

Federal Award Date: 01/15/2021

Recipient Information**1. Recipient Name**

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
[NoPhoneRecord]

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier**7. Project Director or Principal Investigator**

Dr. Elizabeth Rausch-Phung
Director, Bureau of Immunization
elizabeth.rausch-phung@health.ny.gov
(518) 473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

Candelaria Rijo
cqr5@cdc.gov
404-639-8526

Federal Award Information**11. Award Number**

6 NH23IP922625-02-03

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

14. Federal Award Project Title

CDC-RFA-IP19-1901 Immunization and Vaccines for Children

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2020 - **End Date** 06/30/2021**20. Total Amount of Federal Funds Obligated by this Action** \$100,449,264.00

20a. Direct Cost Amount \$100,449,264.00

20b. Indirect Cost Amount \$0.00

21. Authorized Carryover \$0.00**22. Offset** \$0.00**23. Total Amount of Federal Funds Obligated this budget period** \$25,210,811.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$125,660,075.00**26. Project Period Start Date** 07/01/2019 - **End Date** 06/30/2024**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period** \$144,243,871.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer – Signature

Freda Johnson

30. Remarks

**Recipient Information****Recipient Name**

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
[NoPhoneRecord]

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Cooperative Agreement

32. Type of Award

Demonstration

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$4,033,723.00
b. Fringe Benefits	\$2,384,736.00
c. Total Personnel Costs	\$6,418,459.00
d. Equipment	\$8,000.00
e. Supplies	\$257,000.00
f. Travel	\$102,535.00
g. Construction	\$0.00
h. Other	\$100,898,407.00
i. Contractual	\$17,141,275.00
j. TOTAL DIRECT COSTS	\$124,825,676.00
k. INDIRECT COSTS	\$834,399.00
l. TOTAL APPROVED BUDGET	\$125,660,075.00
m. Federal Share	\$125,660,075.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390GKL	20NH23IP922625C5	IP	41.51	\$100,449,264.00	75-2124-0943



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-03

FAIN# NH23IP922625

Federal Award Date: 01/15/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH, NEW YORK DEPARTMENT OF

6 NH23IP922625-02-03

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19-1901, entitled, *Immunization and Vaccines for Children*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount \$100,449,264 is approved for the Year 02 budget period, which is July 1, 2020 through June 30, 2021.

The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
COVID-19	\$100,449,264

Recipients have until June 30, 2024 to expend all COVID-19 funds herein and previously funded.

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); and/or the Consolidated Appropriations Act, 2021, Division M – Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-266), agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting [guidance](https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf) is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to

COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-IP19-1901 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 – Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification within 45 days of receipt of the Notice of Award. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

ADMINISTRATIVE REQUIREMENTS

The recipient must respond to the comments in the technical review and/or OGS Budget Comments in accordance with the recommendations provided in GrantSolutions as a Grant Note within 45 days of receipt of the Notice of Award. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services

Wayne Woods, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS-TV-2
Atlanta, GA 30341
Email: kuv1@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures,
Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be known in order to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT S



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-04

FAIN# NH23IP922625

Federal Award Date: 03/31/2021

Recipient Information**1. Recipient Name**

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
[NoPhoneRecord]

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier**7. Project Director or Principal Investigator**

Dr. Elizabeth Rausch-Phung
Director, Bureau of Immunization
elizabeth.rausch-phung@health.ny.gov
(518) 473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

Candelaria Rijo
cqr5@cdc.gov
404-639-8526

Federal Award Information**11. Award Number**

6 NH23IP922625-02-04

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

14. Federal Award Project Title

CDC-RFA-IP19-1901 Immunization and Vaccines for Children

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2020 - **End Date** 06/30/2021**20. Total Amount of Federal Funds Obligated by this Action** \$100,449,263.00

20a. Direct Cost Amount \$100,449,263.00

20b. Indirect Cost Amount \$0.00

21. Authorized Carryover \$0.00**22. Offset** \$0.00**23. Total Amount of Federal Funds Obligated this budget period** \$125,660,075.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$226,109,338.00**26. Project Period Start Date** 07/01/2019 - **End Date** 06/30/2024**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period** \$244,693,134.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Freda Johnson

30. Remarks

This funding is related to the activities under COVID-19 Vaccination Supplement 4 (April 2021)

**Recipient Information****Recipient Name**

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
[NoPhoneRecord]

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Cooperative Agreement

32. Type of Award

Demonstration

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$4,033,723.00
b. Fringe Benefits	\$2,384,736.00
c. Total Personnel Costs	\$6,418,459.00
d. Equipment	\$8,000.00
e. Supplies	\$257,000.00
f. Travel	\$102,535.00
g. Construction	\$0.00
h. Other	\$201,347,670.00
i. Contractual	\$17,141,275.00
j. TOTAL DIRECT COSTS	\$225,274,939.00
k. INDIRECT COSTS	\$834,399.00
l. TOTAL APPROVED BUDGET	\$226,109,338.00
m. Federal Share	\$226,109,338.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390GKL	20NH23IP922625C5	IP	41.51	\$43,193,183.00	75-2124-0943
1-9390GWA	20NH23IP922625C6	IP	41.51	\$57,256,080.00	75-X-0943



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-04

FAIN# NH23IP922625

Federal Award Date: 03/31/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH, NEW YORK DEPARTMENT OF

6 NH23IP922625-02-04

1. Terms and Conditions-New York

ADDITIONAL TERMS AND CONDITIONS OF AWARD

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19- 1901, entitled, *Immunization and Vaccines for Children*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount \$100,449,263 is approved for the Year 02 budget period, which is July 1, 2020 through June 30, 2021.

Recipients have until June 30, 2024 to expend all COVID-19 funds herein and previously funded.

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); and/or the Consolidated Appropriations Act, 2021, Division M - Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260), the American Rescue Plan Act of 2021 (P.L. 117-2) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS-CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting [guidance](https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf) is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - o Other than for normal and recognized executive-legislative relationships, no funds may be used for:

- publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
- the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
- o See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-IP19-1901 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 - Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification within 60 days of receipt of the Notice of Award. If the date falls on a weekend or holiday, the submission will be due the following business day. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Wayne Woods, Grants Management Specialist Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS-TV-2 Atlanta, GA 30341
Email: kuv1@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)
AND

U.S. Department of Health and Human Services Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator 3301 Independence Avenue, SW Cohen
Building, Room 5527 Washington, DC 20201
Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email:
MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1- 800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhtips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of **Page 2** of the Notice of Award must be known to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT T



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-06

FAIN# NH23IP922625

Federal Award Date: 05/03/2021

Recipient Information**1. Recipient Name**

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
[NoPhoneRecord]

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier**7. Project Director or Principal Investigator**

Dr. Elizabeth Rausch-Phung
Director, Bureau of Immunization
elizabeth.rausch-phung@health.ny.gov
(518) 473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

Candelaria Rijo
cqr5@cdc.gov
404-639-8526

Federal Award Information**11. Award Number**

6 NH23IP922625-02-06

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

14. Federal Award Project Title

CDC-RFA-IP19-1901 Immunization and Vaccines for Children

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2020 - **End Date** 06/30/2021**20. Total Amount of Federal Funds Obligated by this Action** \$8,161,503.00

20a. Direct Cost Amount \$8,161,503.00

20b. Indirect Cost Amount \$0.00

21. Authorized Carryover \$0.00**22. Offset** \$0.00**23. Total Amount of Federal Funds Obligated this budget period** \$226,109,338.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$234,270,841.00**26. Project Period Start Date** 07/01/2019 - **End Date** 06/30/2024**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Project Period** Not Available**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Kathy Raible

30. Remarks

**Recipient Information****Recipient Name**

HEALTH, NEW YORK DEPARTMENT OF
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
[NoPhoneRecord]

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier

Not Available

31. Assistance Type

Cooperative Agreement

32. Type of Award

Demonstration

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$4,033,723.00
b. Fringe Benefits	\$2,384,736.00
c. Total Personnel Costs	\$6,418,459.00
d. Equipment	\$8,000.00
e. Supplies	\$383,000.00
f. Travel	\$102,535.00
g. Construction	\$0.00
h. Other	\$109,059,909.00
i. Contractual	\$117,464,539.00
j. TOTAL DIRECT COSTS	\$233,436,442.00
k. INDIRECT COSTS	\$834,399.00
l. TOTAL APPROVED BUDGET	\$234,270,841.00
m. Federal Share	\$234,270,841.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-9390GZB	20NH23IP922625VWCC6	IP	41.51	\$8,161,503.00	75-X-0943



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-02-06

FAIN# NH23IP922625

Federal Award Date: 05/03/2021

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

HEALTH, NEW YORK DEPARTMENT OF

6 NH23IP922625-02-06

1. Revised Terms & Conditions

ADDITIONAL TERMS AND CONDITIONS OF AWARD

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federalregulationspolicies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number IP19- 1901, entitled, *Immunization and Vaccines for Children*, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Component Funding: Additional funding in the amount \$8,161,503 is approved for the Year 02 budget period, which is July 1, 2020 through June 30, 2021.

Recipients have until June 30, 2024 to expend all COVID-19 funds herein and previously funded.6

Overtime: Because overtime costs are a very likely and reasonable expense during the response to COVID-19, CDC will allow recipients to include projected overtime in their budgets. Recipients should be careful to estimate costs based on current real-time needs and will still be required to follow federal rules and regulations in accounting for the employees' time and effort.

Coronavirus Disease 2019 (COVID-19) Funds: A recipient of a grant or cooperative agreement awarded by the Department of Health and Human Services (HHS) with funds made available under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (P.L. 116-123); the Coronavirus Aid, Relief, and Economic Security Act, 2020 (the "CARES Act") (P.L. 116-136); the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139); and/or the Consolidated Appropriations Act, 2021, Division M - Coronavirus Response and Relief Supplemental Appropriations Act, 2021 (P.L. 116-260), the American Rescue Plan Act of 2021 (P.L. 117-2) agrees, as applicable to the award, to: 1) comply with existing and/or future directives and guidance from the Secretary regarding control of the spread of COVID-19; 2) in consultation and coordination with HHS, provide, commensurate with the condition of the individual, COVID-19 patient care regardless of the individual's home jurisdiction and/or appropriate public health measures (e.g., social distancing, home isolation); and 3) assist the United States Government in the implementation and enforcement of federal orders related to quarantine and isolation.

In addition, to the extent applicable, Recipient will comply with Section 18115 of the CARES Act, with respect to the reporting to the HHS Secretary of results of tests intended to detect SARS- CoV-2 or to diagnose a possible case of COVID-19. Such reporting shall be in accordance with guidance and direction from HHS and/or CDC. HHS laboratory reporting [guidance](https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf) is posted at: <https://www.hhs.gov/sites/default/files/covid-19-laboratory-data-reporting-guidance.pdf>.

Further, consistent with the full scope of applicable grant regulations (45 C.F.R. 75.322), the purpose of this award, and the underlying funding, the recipient is expected to provide to CDC copies of and/or access to COVID-19 data collected with these funds, including but not limited to data related to COVID-19 testing. CDC will specify in further guidance and directives what is encompassed by this requirement.

Unallowable Costs:

- Research
- Clinical care
- Publicity and propaganda (lobbying):
 - o Other than for normal and recognized executive-legislative relationships, no funds may be used for:
 - publicity or propaganda purposes, for the preparation, distribution, or use of any material designed to support or defeat the enactment of legislation before any legislative body
 - the salary or expenses of any grant or contract recipient, or agent acting for such recipient, related to any activity designed to influence the enactment of legislation, appropriations, regulation, administrative action, or Executive order proposed or pending before any legislative body
 - o See Additional Requirement (AR) 12 for detailed guidance on this prohibition and additional guidance on lobbying for CDC recipients:
https://www.cdc.gov/grants/documents/Anti-Lobbying_Restrictions_for_CDC_Grantees_July_2012.pdf
- All unallowable costs cited in CDC-RFA-IP19-1901 remain in effect, unless specifically amended in this guidance, in accordance with 45 CFR Part 75 - Uniform Administrative Requirements, Cost Principles, And Audit Requirements for HHS Awards.

COVID-19 Funding Budget Revision Requirement: The recipient must submit a revised budget with a narrative justification by May 31, 2021. If the date falls on a weekend or holiday, the submission will be due the following business day. Failure to submit the required information in a timely manner may adversely affect the future funding of this project. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the Awarding Agency Contact Information section on the first page before the due date.

REPORTING REQUIREMENTS

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services
Wayne Woods, Grants Management Specialist
Centers for Disease Control and Prevention
Branch 1
2939 Flowers Road, MS-TV-2
Atlanta, GA 30341
Email: kuv1@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General

ATTN: Mandatory Grant Disclosures, Intake Coordinator

3301 Independence Avenue, SW

Cohen Building, Room 5527

Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or Email:

MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1- 800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhtips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of **Page 2** of the Notice of Award must be known to draw down funds.

Stewardship: The recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to your cooperative agreement are allowable, allocable, and reasonable and that they address the highest priority needs as they relate to this program.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

EXHIBIT U



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-01

FAIN# NH23IP922625

Federal Award Date: 09/01/2023

Recipient Information**1. Recipient Name**

NYS DEPARTMENT OF HEALTH
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
518-474-4845

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

7. Project Director or Principal Investigator

Ms. Kara Connelly
Assistant Director Bureau of Immunization
kara.connelly@health.ny.gov
518-473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

Candelaria Rijo
cqr5@cdc.gov
404-639-8526

Federal Award Information**11. Award Number**

6 NH23IP922625-05-01

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

14. Federal Award Project Title

Application for Immunization and VFC Cooperative Agreement for supplemental funding to support Immunization Systems and to support administration of vaccine to recently displaced Ukrainians resettled.

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Supplement

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2023 - **End Date** 12/31/2024**20. Total Amount of Federal Funds Obligated by this Action** \$6,789,544.00

20a. Direct Cost Amount \$6,715,935.00

20b. Indirect Cost Amount \$73,609.00

21. Authorized Carryover \$0.00**22. Offset** \$1,118,680.00**23. Total Amount of Federal Funds Obligated this budget period** \$12,174,066.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$18,963,610.00**26. Period of Performance Start Date** 07/01/2019 - **End Date** 12/31/2024**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance** \$301,198,556.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Kathy Raible

30. Remarks

**Recipient Information****Recipient Name**

NYS DEPARTMENT OF HEALTH
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
518-474-4845

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$4,918,554.00
b. Fringe Benefits	\$3,243,704.00
c. Total Personnel Costs	\$8,162,258.00
d. Equipment	\$29,000.00
e. Supplies	\$23,607.00
f. Travel	\$146,631.00
g. Construction	\$0.00
h. Other	\$4,426,772.00
i. Contractual	\$5,857,510.00
j. TOTAL DIRECT COSTS	\$18,645,778.00
k. INDIRECT COSTS	\$1,436,512.00
l. TOTAL APPROVED BUDGET	\$20,082,290.00
m. Federal Share	\$20,082,290.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-93909KZ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
1-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-21-0951
0-9390EWQ	19NH23IP922625C3	IP	41.51	93.268	\$0.00	75-2024-0943
1-9390FG3	20NH23IP922625C3	IP	41.51	93.268	\$0.00	75-2024-0943
1-9390GKL	20NH23IP922625C5	IP	41.51	93.268	\$0.00	75-2124-0943
1-9390GUU	20NH23IP922625UDSPC5	IP	41.51	93.268	\$0.00	75-2124-0943
1-9390GWA	20NH23IP922625C6	IP	41.51	93.268	\$0.00	75-X-0943
1-9390GZB	20NH23IP922625VWCC6	IP	41.51	93.268	\$0.00	75-X-0943
2-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390K3F	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
2-9390K3W	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
2-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-22-0951
2-9390K8W	20NH23IP922625UKR	IP	41.51	93.268	\$0.00	75-2223-0943
2-9390K9M	20NH23IP922625IISC6	IP	41.51	93.268	\$0.00	75-X-0943
3-93909KZ	19NH23IP922625OTBRK	IP	41.51	93.268	\$0.00	75-X-0951
3-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390K3F	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
3-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-23-0951
3-9390LR9	19NH23IP922625	IP	41.51	93.268	\$6,074,239.00	75-X-0140
3-939ZRYH	19NH23IP922625	IP	41.51	93.268	\$715,305.00	75-23-0951



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-01

FAIN# NH23IP922625

Federal Award Date: 09/01/2023

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

NYS DEPARTMENT OF HEALTH

6 NH23IP922625-05-01

1. Terms and Conditions

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at <https://www.cdc.gov/grants/federal-regulations-policies/index.html>, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number CDC-RFA-IP19-1901, titled Immunization and Vaccines for Children, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Supplemental Extension: This amendment approves a 6-month extension with additional funds in the amount of \$6,789,544. The budget and project period end dates have been extended from June 30, 2024, to December 31, 2024.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third-party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Component/Project Funding: The NOFO provides for the funding of multiple components under this award. The approved component funding levels for this notice of award are:

NOFO Component	Amount
HHS Bridge Access	\$3,867,264
Vaccine Confidence	\$715,305
BY05 CORE - IIS	\$2,206,975

Summary Statement/Technical Review: Within 5 days of this Notice of Award's (NoA) issue date, the Summary Statement/Technical Review will be accessible to the recipient in GrantSolutions Grant Notes. Contact the assigned Program Officer indicated in the NoA with any questions regarding this document or any follow up requirements.

Budget Revision Requirement: By October 31, 2023, the recipient must submit a detailed budget with a narrative justification and a detailed workplan as a budget revision amendment in GrantSolutions. If the information cannot be provided by the due date, you are required to contact the GMS/GMO identified in the CDC Staff Contacts section of this notice before the due date.

A detailed budget is needed for the CORE-IIS component.

Administrative Requirements: Per review of the budget, the recipient must respond to the following OGS Budget Comments:

- I. **Personnel-** Provide names of TBD Personnel upon selection.
- II. **Equipment-**
 - A. Items requested are not above the \$5,000 threshold for Equipment in accordance with CDC Budget Preparation Guidelines.
 - B. Vaccine Refrigerators and Freezers (HHS Bridge Access Program) must be discussed further with PO and GMS to verify need before purchased. OGS normally does not purchase these items this late in a project period.

- III. **Supplies-** Portable Vaccine Coolers (HHS Bridge Access Program) must be discussed further with PO and GMS to verify need before purchased. OGS normally does not purchase these items this late in a project period.
- IV. **Contractors-** Provide name of TBD Contractors upon Selection (HHS Bridge Access Program; Vaccine Confidence Program).

Missing Contractual Elements – The contracts listed in the budget are approved, however, the recipient must provide *names of TBD Contractors*, via GrantSolutions as a Grant Note prior to beginning work on the contracts.

REPORTING REQUIREMENTS

Annual Federal Financial Report (FFR SF-425): Annual financial reporting is required every twelve-month period. Due to the approved extension period, the final budget period has been extended and an additional annual financial report will be required. A completed FFR SF-425 covering the original final budget period of **July 01, 2023**, to **June 30, 2024**, must be submitted by **September 30, 2024**.

Recipients must submit all closeout reports identified in this section within 90 days of the period of performance end date. The reporting timeframe is the full period of performance. Failure to submit timely and accurate final reports may affect future funding to the organization or awards under the direction of the same Project Director/Principal Investigator (PD/PI).

Final Performance Progress and Evaluation Report (PPER): This report should include the information specified in the NOFO. At a minimum, the report will include the following:

- Statement of progress made toward the achievement of originally stated aims.
- Description of results (positive or negative) considered significant.
- List of publications resulting from the project, with plans, if any, for further publication.

All manuscripts published as a result of the work supported in part or whole by the cooperative grant must be submitted with the performance progress reports.

Final Federal Financial Report (FFR, SF-425): The FFR should only include those funds authorized and expended during the timeframe covered by the report. The Final FFR, SF-425 is required and must be submitted no later than 90 days after the period of performance end date. The final report must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. Should the amount not match with the final expenditures reported to the Department of Health and Human Services' PMS, you will be required to update your reports to PMS accordingly. Remaining unobligated funds will be de-obligated and returned to the U.S. Treasury.

Electronic versions of the form can be downloaded at:

<https://www.grants.gov/web/grants/forms/post-award-reporting-forms.html#sortby=1>

Equipment and Supplies - Tangible Personal Property Report (SF-428): A completed Tangible Personal Property Report SF-428 and Final Report SF-428B addendum must be submitted, along with any Supplemental Sheet SF-428S detailing all major equipment acquired or furnished under this project with a unit acquisition cost of \$5,000 or more. Electronic versions

of the forms can be downloaded by visiting: <https://www.grants.gov/web/grants/forms/post-award-reporting-forms.html#sortBy=1>

If no equipment was acquired under an award, a negative report is required.

The recipient must identify each item of equipment that it wishes to retain for continued use in accordance with 45 CFR Part 75. The awarding agency may exercise its rights to require the transfer of equipment purchased under the assistance award. CDC will notify the recipient if transfer to title will be required and provide disposition instruction on all major equipment.

Equipment with a unit acquisition cost of less than \$5,000 that is no longer to be used in projects or programs currently or previously sponsored by the Federal Government may be retained, sold, or otherwise disposed of, with no further obligation to the Federal Government.

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of **Page 2** of the Notice of Award must be known to draw down funds.

EXHIBIT V



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-09

FAIN# NH23IP922625

Federal Award Date: 11/01/2024

Recipient Information**1. Recipient Name**

NYS DEPARTMENT OF HEALTH
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
518-474-4845

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

7. Project Director or Principal Investigator

Ms. Kara Connelly
Assistant Director Bureau of Immunization
kara.connelly@health.ny.gov
518-473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

James Lueken
Program Officer
oqh7@cdc.gov
4047187232

Federal Award Information**11. Award Number**

6 NH23IP922625-05-09

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

14. Federal Award Project Title

Application for BY5 Supplement Extension for Immunization VFC Cooperative Agreement

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Budget Revision

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2023 - **End Date** 06/30/2025**20. Total Amount of Federal Funds Obligated by this Action** \$0.00

20a. Direct Cost Amount \$20,207.00

20b. Indirect Cost Amount (\$20,207.00)

21. Authorized Carryover \$56,334,476.00**22. Offset** \$2,278,461.00**23. Total Amount of Federal Funds Obligated this budget period** \$37,580,703.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$37,580,703.00**26. Period of Performance Start Date** 07/01/2019 - **End Date** 06/30/2025**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance** \$319,815,649.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Kathy Raible
Grants Management Officer

30. Remarks

**Recipient Information****Recipient Name**

NYS DEPARTMENT OF HEALTH
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
518-474-4845

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages

\$13,134,966.00

b. Fringe Benefits

\$8,630,644.00

c. Total Personnel Costs

\$21,765,610.00

d. Equipment

\$47,750.00

e. Supplies

\$384,872.00

f. Travel

\$307,199.00

g. Construction

\$0.00

h. Other

\$7,070,561.00

i. Contractual

\$62,916,767.00

j. TOTAL DIRECT COSTS

\$92,492,759.00

k. INDIRECT COSTS

\$3,700,881.00

l. TOTAL APPROVED BUDGET

\$96,193,640.00

m. Federal Share

\$96,193,640.00

n. Non-Federal Share

\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	ASSISTANCE LISTING	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-93909KZ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
1-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-21-0951
0-9390EWQ	19NH23IP922625C3	IP	41.51	93.268	\$0.00	75-2024-0943
1-9390FG3	20NH23IP922625C3	IP	41.51	93.268	\$0.00	75-2024-0943
1-9390GKL	20NH23IP922625C5	IP	41.51	93.268	\$0.00	75-2124-0943
1-9390GUU	20NH23IP922625UDSPC5	IP	41.51	93.268	\$0.00	75-2124-0943
1-9390GWA	20NH23IP922625C6	IP	41.51	93.268	\$0.00	75-X-0943
1-9390GZB	20NH23IP922625VWCC6	IP	41.51	93.268	\$0.00	75-X-0943
2-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390K3F	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
2-9390K3W	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
2-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-22-0951
2-9390K8W	20NH23IP922625UKR	IP	41.51	93.268	\$0.00	75-2223-0943
2-9390K9M	20NH23IP922625IISC6	IP	41.51	93.268	\$0.00	75-X-0943
3-93909KZ	19NH23IP922625OTBRK	IP	41.51	93.268	\$0.00	75-X-0951
3-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390K3F	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
3-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-23-0951
3-9390LR9	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0140
3-939ZRYH	19NH23IP922625	IP	41.51	93.268	\$0.00	75-23-0951
4-9390MV2	20NH23IP922625IISC5	IP	41.51	93.268	\$0.00	75-2124-0943
4-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
4-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-09

FAIN# NH23IP922625

Federal Award Date: 11/01/2024

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	ASSISTANCE LISTING	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
4-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
4-9390MPT	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
4-9390MV2	19NH23IP922625HSC5	IP	41.51	93.268	\$0.00	75-2124-0943
4-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-24-0951
4-939ZRYH	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
4-9390MFC	19NH23IP922625C5	IP	41.51	93.268	\$0.00	75-2124-0943



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-09

FAIN# NH23IP922625

Federal Award Date: 11/01/2024

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

NYS DEPARTMENT OF HEALTH

6 NH23IP922625-05-09

1. Terms and Conditions

ADDITIONAL TERMS AND CONDITIONS

Revised Budget: The purpose of this amended Notice of Award is to approve the **revised budget** submitted by your organization dated September 30, 2024. Funds have been distributed as indicated in the approved budget of this Notice of Award.

All the other terms and conditions issued with the original award remain in effect throughout the budget period unless otherwise changed, in writing, by the Grants Management Officer.

Please be advised that recipient must exercise proper stewardship over Federal funds by ensuring that all costs charged to their cooperative agreement are allowable, allocable, necessary, and reasonable.

PLEASE REFERENCE AWARD NUMBER ON ALL CORRESPONDENCE

EXHIBIT W



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-08

FAIN# NH23IP922625

Federal Award Date: 09/11/2024

Recipient Information**1. Recipient Name**

NYS DEPARTMENT OF HEALTH
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
518-474-4845

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

7. Project Director or Principal Investigator

Ms. Kara Connelly
Assistant Director Bureau of Immunization
kara.connelly@health.ny.gov
518-473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

James Lueken
Program Officer
oqh7@cdc.gov
4047187232

Federal Award Information**11. Award Number**

6 NH23IP922625-05-08

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

14. Federal Award Project Title

Application for BY5 Supplement Extension for Immunization VFC Cooperative Agreement

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Carryover of Funds

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2023 - **End Date** 06/30/2025**20. Total Amount of Federal Funds Obligated by this Action**

\$0.00

20a. Direct Cost Amount

\$55,175,894.00

20b. Indirect Cost Amount

\$658,582.00

21. Authorized Carryover

\$56,334,476.00

22. Offset

\$2,278,461.00

23. Total Amount of Federal Funds Obligated this budget period

\$37,580,703.00

24. Total Approved Cost Sharing or Matching, where applicable

\$0.00

25. Total Federal and Non-Federal Approved this Budget Period

\$37,580,703.00

26. Period of Performance Start Date 07/01/2019 - **End Date** 06/30/2025**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance**

\$319,815,649.00

28. Authorized Treatment of Program Income

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Kathy Raible1
Grants Management Officer

30. Remarks

**Recipient Information****Recipient Name**

NYS DEPARTMENT OF HEALTH
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
518-474-4845

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages	\$13,133,319.00
b. Fringe Benefits	\$8,597,930.00
c. Total Personnel Costs	\$21,731,249.00
d. Equipment	\$47,750.00
e. Supplies	\$384,872.00
f. Travel	\$312,998.00
g. Construction	\$0.00
h. Other	\$7,859,309.00
i. Contractual	\$62,136,374.00
j. TOTAL DIRECT COSTS	\$92,472,552.00
k. INDIRECT COSTS	\$3,721,088.00
l. TOTAL APPROVED BUDGET	\$96,193,640.00
m. Federal Share	\$96,193,640.00
n. Non-Federal Share	\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
1-93909KZ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
1-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
1-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-21-0951
0-9390EWQ	19NH23IP922625C3	IP	41.51	93.268	\$0.00	75-2024-0943
1-9390FG3	20NH23IP922625C3	IP	41.51	93.268	\$0.00	75-2024-0943
1-9390GKL	20NH23IP922625C5	IP	41.51	93.268	\$0.00	75-2124-0943
1-9390GUU	20NH23IP922625UDSPC5	IP	41.51	93.268	\$0.00	75-2124-0943
1-9390GWA	20NH23IP922625C6	IP	41.51	93.268	\$0.00	75-X-0943
1-9390GZB	20NH23IP922625VWCC6	IP	41.51	93.268	\$0.00	75-X-0943
2-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
2-9390K3F	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
2-9390K3W	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
2-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-22-0951
2-9390K8W	20NH23IP922625UKR	IP	41.51	93.268	\$0.00	75-2223-0943
2-9390K9M	20NH23IP922625IISC6	IP	41.51	93.268	\$0.00	75-X-0943
3-93909KZ	19NH23IP922625OTBRK	IP	41.51	93.268	\$0.00	75-X-0951
3-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
3-9390K3F	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
3-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-23-0951
3-9390LR9	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0140
3-939ZRYH	19NH23IP922625	IP	41.51	93.268	\$0.00	75-23-0951
4-9390MV2	20NH23IP922625IISC5	IP	41.51	93.268	\$0.00	75-2124-0943
4-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
4-9390BKJ	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-08

FAIN# NH23IP922625

Federal Award Date: 09/11/2024

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	CFDA NO.	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
4-9390BKM	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009
4-9390MPT	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
4-9390MV2	19NH23IP922625IISC5	IP	41.51	93.268	\$0.00	75-2124-0943
4-939ZRWL	19NH23IP922625	IP	41.51	93.268	\$0.00	75-24-0951
4-939ZRYH	19NH23IP922625	IP	41.51	93.268	\$0.00	75-X-0951
4-9390MFC	19NH23IP922625C5	IP	41.51	93.268	\$0.00	75-2124-0943



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-08

FAIN# NH23IP922625

Federal Award Date: 09/11/2024

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

NYS DEPARTMENT OF HEALTH

6 NH23IP922625-05-08

1. Terms and Conditions

ADDITIONAL TERMS AND CONDITIONS

Carryover: The purpose of this amended Notice of Award is to approve carryover of unobligated funds in the amount of \$55,834,476 from budget periods **YR01 to YR04** to budget period **YR05**. This is in response to a request submitted by your organization dated August 29, 2024. These funds have been distributed as indicated in the approved budget of this Notice of Award.

Unobligated funds in the amount of \$55,834,476 have been applied to this award. Please note that if the actual amount of available unobligated funds is less than the amount used in this action, then the total approved budget may be reduced by the difference in a subsequent award action, thus reducing the amount of the current award.

Administrative Requirements: The recipient must adhere to the information below in the carryover budget:

- **Equipment:** The purchase of iPads and Apple Folio Cases should be included in the Supplies budget category.
- **Equipment:** Extended Warranties and Service Plans of iPads and Apple Folio Cases should be included in the Other budget category.

These funds are approved for the current fiscal year budget period only with no commitment for continued support in future budget periods.

All other terms and conditions of the cooperative agreement remain unchanged and in full effect.

Please be advised that grantee must exercise proper stewardship over Federal funds by ensuring that all costs charged to their cooperative agreement are allowable, allocable, and reasonable.

PLEASE REFERENCE AWARD NUMBER ON ALL CORRESPONDENCE

EXHIBIT X



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-10

FAIN# NH23IP922625

Federal Award Date: 03/24/2025

Recipient Information**1. Recipient Name**

NYS DEPARTMENT OF HEALTH
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
518-474-4845

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

7. Project Director or Principal Investigator

Ms. Kara Connelly
Assistant Director Bureau of Immunization
kara.connelly@health.ny.gov
518-473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

Nancy Wong
Program Officer
nbb9@cdc.gov
786-777-8767

Federal Award Information**11. Award Number**

6 NH23IP922625-05-10

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

14. Federal Award Project Title

Application for BY5 Supplement Extension for Immunization VFC Cooperative Agreement

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Administrative Action

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2023 - **End Date** 03/24/2025**20. Total Amount of Federal Funds Obligated by this Action** \$0.00

20a. Direct Cost Amount \$0.00

20b. Indirect Cost Amount \$0.00

21. Authorized Carryover \$56,334,476.00**22. Offset** \$2,278,461.00**23. Total Amount of Federal Funds Obligated this budget period** \$37,580,703.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$37,580,703.00**26. Period of Performance Start Date** 07/01/2019 - **End Date** 03/24/2025**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance** \$319,815,649.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Percy Jernigan

30. Remarks

Department Authority

**Recipient Information****Recipient Name**

NYS DEPARTMENT OF HEALTH

Empire State Plaza

NY State Dept. Of Health

Albany, NY 12237-0001

518-474-4845

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages

\$13,134,966.00

b. Fringe Benefits

\$8,630,644.00

c. Total Personnel Costs

\$21,765,610.00

d. Equipment

\$47,750.00

e. Supplies

\$384,872.00

f. Travel

\$307,199.00

g. Construction

\$0.00

h. Other

\$7,070,561.00

i. Contractual

\$62,916,767.00

j. TOTAL DIRECT COSTS

\$92,492,759.00

k. INDIRECT COSTS

\$3,700,881.00

l. TOTAL APPROVED BUDGET

\$96,193,640.00

m. Federal Share

\$96,193,640.00

n. Non-Federal Share

\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	ASSISTANCE LISTING	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
0-9390EWQ	19NH23IP922625C3	IP	41.51	93.268	\$0.00	75-2024-0943
1-9390FG3	20NH23IP922625C3	IP	41.51	93.268	\$0.00	75-2024-0943
1-9390GKL	20NH23IP922625C5	IP	41.51	93.268	\$0.00	75-2124-0943
1-9390GUU	20NH23IP922625UDSPC5	IP	41.51	93.268	\$0.00	75-2124-0943
1-9390GWA	20NH23IP922625C6	IP	41.51	93.268	\$0.00	75-X-0943
2-9390K9M	20NH23IP922625IISC6	IP	41.51	93.268	\$0.00	75-X-0943



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-10

FAIN# NH23IP922625

Federal Award Date: 03/24/2025

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

AWARD ATTACHMENTS

NYS DEPARTMENT OF HEALTH

6 NH23IP922625-05-10

1. Terms & Conditions

TERMS AND CONDITIONS OF AWARD

Termination: The purpose of this amendment is to terminate the use of any remaining COVID-19 funding associated with this award. The termination of this funding is for cause. HHS regulations permit termination if “the non-Federal entity fails to comply with the terms and conditions of the award”, or separately, “for cause.” The end of the pandemic provides cause to terminate COVID-related grants and cooperative agreements. These grants and cooperative agreements were issued for a limited purpose: to ameliorate the effects of the pandemic. Now that the pandemic is over, the grants and cooperative agreements are no longer necessary as their limited purpose has run out. Termination of use of funding under the listed document number(s) is effective as of the date set out in your Notice of Award.

Impacted document numbers are included on page 2 of this Notice of Award (NoA).

No additional activities can be conducted, and no additional costs may be incurred, as it relates to these funds. Unobligated award balances of COVID-19 funding will be de-obligated by CDC. Award activities under other funding may continue consistent with the terms and conditions of the award.

Final Federal Financial Report (FFR, SF-425): Within 30 days please submit final FFR’s for impacted document numbers. The FFR should only include those funds authorized and expended during the timeframe covered by the report. The final report must indicate the exact balance of unobligated funds and may not reflect any unliquidated obligations. Should the amount not match with the final expenditures reported to the Payment Management System (PMS), you will be required to update your reports to PMS accordingly.

All other terms and conditions of this award remain in effect.

EXHIBIT Y



Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-11

FAIN# NH23IP922625

Federal Award Date: 03/25/2025

Recipient Information**1. Recipient Name**

NYS DEPARTMENT OF HEALTH
Empire State Plaza
NY State Dept. Of Health
Albany, NY 12237-0001
518-474-4845

2. Congressional District of Recipient
20**3. Payment System Identifier (ID)**

1146013200R9

4. Employer Identification Number (EIN)

146013200

5. Data Universal Numbering System (DUNS)

806781340

6. Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

7. Project Director or Principal Investigator

Ms. Kara Connelly
Assistant Director Bureau of Immunization
kara.connelly@health.ny.gov
518-473-4437

8. Authorized Official

Mr. Andrew T. Ruby
Deputy Director
andrew.ruby@health.ny.gov
518-474-1208

Federal Agency Information

CDC Office of Financial Resources

9. Awarding Agency Contact Information

Wayne Woods
kuv1@cdc.gov
770-488-2948

10. Program Official Contact Information

Nancy Wong
Program Officer
nbb9@cdc.gov
786-777-8767

Federal Award Information**11. Award Number**

6 NH23IP922625-05-11

12. Unique Federal Award Identification Number (FAIN)

NH23IP922625

13. Statutory Authority

Sections 317, 317(k)(2) of the Public Health Service Act (42 U.S.C. Sections 247b, 247b(k)(2) and 247c), as amended.

14. Federal Award Project Title

Application for BY5 Supplement Extension for Immunization VFC Cooperative Agreement

15. Assistance Listing Number

93.268

16. Assistance Listing Program Title

Immunization Cooperative Agreements

17. Award Action Type

Administrative Action

18. Is the Award R&D?

No

Summary Federal Award Financial Information**19. Budget Period Start Date** 07/01/2023 - **End Date** 06/30/2025**20. Total Amount of Federal Funds Obligated by this Action** \$0.00

20a. Direct Cost Amount \$0.00

20b. Indirect Cost Amount \$0.00

21. Authorized Carryover \$56,334,476.00**22. Offset** \$2,278,461.00**23. Total Amount of Federal Funds Obligated this budget period** \$37,580,703.00**24. Total Approved Cost Sharing or Matching, where applicable** \$0.00**25. Total Federal and Non-Federal Approved this Budget Period** \$37,580,703.00**26. Period of Performance Start Date** 07/01/2019 - **End Date** 06/30/2025**27. Total Amount of the Federal Award including Approved Cost Sharing or Matching this Period of Performance** \$319,815,649.00**28. Authorized Treatment of Program Income**

ADDITIONAL COSTS

29. Grants Management Officer - Signature

Percy Jernigan

30. Remarks

: This is an internal administrative action. No action is required from the recipient.

**Recipient Information****Recipient Name**

NYS DEPARTMENT OF HEALTH

Empire State Plaza

NY State Dept. Of Health

Albany, NY 12237-0001

518-474-4845

Congressional District of Recipient

20

Payment Account Number and Type

1146013200R9

Employer Identification Number (EIN) Data

146013200

Universal Numbering System (DUNS)

806781340

Recipient's Unique Entity Identifier (UEI)

F863WQVMZSK7

31. Assistance Type

Cooperative Agreement

32. Type of Award

Other

33. Approved Budget

(Excludes Direct Assistance)

I. Financial Assistance from the Federal Awarding Agency Only

II. Total project costs including grant funds and all other financial participation

a. Salaries and Wages

\$13,134,966.00

b. Fringe Benefits

\$8,630,644.00

c. Total Personnel Costs

\$21,765,610.00

d. Equipment

\$47,750.00

e. Supplies

\$384,872.00

f. Travel

\$307,199.00

g. Construction

\$0.00

h. Other

\$7,070,561.00

i. Contractual

\$62,916,767.00

j. TOTAL DIRECT COSTS

\$92,492,759.00

k. INDIRECT COSTS

\$3,700,881.00

l. TOTAL APPROVED BUDGET

\$96,193,640.00

m. Federal Share

\$96,193,640.00

n. Non-Federal Share

\$0.00

34. Accounting Classification Codes

FY-ACCOUNT NO.	DOCUMENT NO.	ADMINISTRATIVE CODE	OBJECT CLASS	ASSISTANCE LISTING	AMT ACTION FINANCIAL ASSISTANCE	APPROPRIATION
4-9390BKG	19NH23IP922625	IP	41.51	93.268	\$0.00	75-75-X-0512-009



DEPARTMENT OF HEALTH AND HUMAN SERVICES Notice of Award

Centers for Disease Control and Prevention

Award# 6 NH23IP922625-05-11

FAIN# NH23IP922625

Federal Award Date: 03/25/2025

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

EXHIBIT Z

Immunization Services Division

No Cost Extension (NCE) Request for IP19-1901 COVID Awards

Recipient: New York State - NH23-IP922603

Directions:

1. For each of the 8 awards noted below, check the boxes next to the awards you wish to request a 24-month NCE. This will extend the awards out to 6/30/2027.
2. Check the appropriate box to indicate the primary reason(s) for remaining funds. Please focus on the reasons that caused the most significant delay and utilize the free-text field to provide any additional context.
3. If the funds will be used to purchase COVID-19 vaccines for adults, check the "yes" box.
4. Check the box signifying that you anticipate completing your activities prior to 6/30/2027.
5. Provide any additional text in the open text field.

1.

Award Title	1901 Immunization and Vaccines for Children (FY 2024 Vaccine Confidence)
PMS Document Number	19NH23IP922625C5
Budget Year (BY)	2024 (BY 5E)
Award Total	\$1,000,000
Unobligated	\$1,000,000

- ☒ Yes, I wish to request a 24-month NCE to complete previously approved activities for the award listed above. Please mark the reason(s) funds remain on the award you are requesting a NCE on:
- ☐ Delay in securing spend authority from state, county, city, or territorial legislature.
- ☒ Significant delay in hiring one or more positions and/or significant attrition resulting in cost savings from personnel.
- ☒ Significant delay in executing contract(s) critical to the success of your approved activities.
- ☐ Other (please specify):
- ☐ Yes, some of this funding will be used to purchase COVID-19 vaccines for adults.
- ☒ Yes, under a 24-mo NCE, approved activities will be successfully completed.
- ☒ Yes, confirming that activities, workplans, and budgets align with the previously approved activities for the 24-mo NCE period.
- ☒ Yes, understand that progress will be monitored on a quarterly basis, including financial reporting.
- ☐ Other additional context:

2.

Award Title	1901 Immunization and Vaccines for Children (FLU/COVID)
PMS Document Number	19NH23IP922625C3
Budget Year (BY)	2020 (BY 2)
Award Total	\$5,277,968
Unobligated	\$489,618

☐ Yes, I wish to request a 24-month NCE to complete previously approved activities for the award listed above.
Please mark the reason(s) funds remain on the award you are requesting a NCE on:

- ☐ Delay in securing spend authority from state, county, city, or territorial legislature.
- ☐ Significant delay in hiring one or more positions and/or significant attrition resulting in cost savings from personnel.
- ☐ Significant delay in executing contract(s) critical to the success of your approved activities.
- ☐ Other (please specify):

- ☐ Yes, some of this funding will be used to purchase COVID-19 vaccines for adults.
- ☐ Yes, under a 24-mo NCE, approved activities will be successfully completed.
- ☐ Yes, confirming that activities, workplans, and budgets align with the previously approved activities for the 24-mo NCE period.
- ☐ Yes, understand that progress will be monitored on a quarterly basis, including financial reporting.
- ☐ Other additional context:

3.

Award Title	1901 Immunization and Vaccines for Children (COVID 2)
PMS Document Number	20NH23IP922625C3
Budget Year (BY)	2021 (BY 3)
Award Total	\$5,277,968
Unobligated	\$925,651

☐ Yes, I wish to request a 24-month NCE to complete previously approved activities for the award listed above.
Please mark the reason(s) funds remain on the award you are requesting a NCE on:

- ☐ Delay in securing spend authority from state, county, city, or territorial legislature.
- ☐ Significant delay in hiring one or more positions and/or significant attrition resulting in cost savings from personnel.
- ☐ Significant delay in executing contract(s) critical to the success of your approved activities.
- ☐ Other (please specify):

- ☐ Yes, some of this funding will be used to purchase COVID-19 vaccines for adults.
- ☐ Yes, under a 24-mo NCE, approved activities will be successfully completed.
- ☐ Yes, confirming that activities, workplans, and budgets align with the previously approved activities for the 24-mo NCE period.
- ☐ Yes, understand that progress will be monitored on a quarterly basis, including financial reporting.
- ☐ Other additional context:

4.

Award Title	1901 Immunization and Vaccines for Children (COVID 4 Vaccine Confidence)
PMS Document Number	20NH23IP922625VWCC6
Budget Year (BY)	2021 (BY 3)
Award Total	\$8,161,503
Unobligated	\$2,946,983

☐ Yes, I wish to request a 24-month NCE to complete previously approved activities for the award listed above.
Please mark the reason(s) funds remain on the award you are requesting a NCE on:

- ☐ Delay in securing spend authority from state, county, city, or territorial legislature.
- ☐ Significant delay in hiring one or more positions and/or significant attrition resulting in cost savings from personnel.
- ☐ Significant delay in executing contract(s) critical to the success of your approved activities.
- ☐ Other (please specify):

- ☐ Yes, some of this funding will be used to purchase COVID-19 vaccines for adults.
- ☐ Yes, under a 24-mo NCE, approved activities will be successfully completed.
- ☐ Yes, confirming that activities, workplans, and budgets align with the previously approved activities for the 24-mo NCE period.
- ☐ Yes, understand that progress will be monitored on a quarterly basis, including financial reporting.
- ☐ Other additional context:

5.

Award Title	1901 Immunization and Vaccines for Children (COVID 3 Priority Populations)
PMS Document Number	20NH23IP922625UDSPC5
Budget Year (BY)	2021 (BY 3)
Award Total	\$11,958,985
Unobligated	\$8,976,190

☒ Yes, I wish to request a 24-month NCE to complete previously approved activities for the award listed above.
Please mark the reason(s) funds remain on the award you are requesting a NCE on:

- ☐ Delay in securing spend authority from state, county, city, or territorial legislature.
- ☐ Significant delay in hiring one or more positions and/or significant attrition resulting in cost savings from personnel.
- ☒ Significant delay in executing contract(s) critical to the success of your approved activities.
- ☐ Other (please specify):

- ☐ Yes, some of this funding will be used to purchase COVID-19 vaccines for adults.
- ☒ Yes, under a 24-mo NCE, approved activities will be successfully completed.
- ☒ Yes, confirming that activities, workplans, and budgets align with the previously approved activities for the 24-mo NCE period.
- ☒ Yes, understand that progress will be monitored on a quarterly basis, including financial reporting.
- ☒ Other additional context: Request for \$4,123,185.30 per carry-forward request.

6.

Award Title	1901 Immunization and Vaccines for Children (COVID 4)
PMS Document Number	20NH23IP922625C6
Budget Year (BY)	2021 (BY 3)
Award Total	\$57,256,080
Unobligated	\$24,899,319

- ☒ Yes, I wish to request a 24-month NCE to complete previously approved activities for the award listed above. Please mark the reason(s) funds remain on the award you are requesting a NCE on:
- ☐ Delay in securing spend authority from state, county, city, or territorial legislature.
 - ☐ Significant delay in hiring one or more positions and/or significant attrition resulting in cost savings from personnel.
 - ☒ Significant delay in executing contract(s) critical to the success of your approved activities.
 - ☐ Other (please specify):
- ☐ Yes, some of this funding will be used to purchase COVID-19 vaccines for adults.
- ☒ Yes, under a 24-mo NCE, approved activities will be successfully completed.
- ☒ Yes, confirming that activities, workplans, and budgets align with the previously approved activities for the 24-mo NCE period.
- ☒ Yes, understand that progress will be monitored on a quarterly basis, including financial reporting.
- ☒ Other additional context: Request for \$40,798,962.24 per carry-forward request.

7.

Award Title	1901 Immunization and Vaccines for Children (COVID 3 & 4)
PMS Document Number	20NH23IP922625C5
Budget Year (BY)	2021 (BY 3)
Award Total	\$131,683,462
Unobligated	\$43,304,409

- ☒ Yes, I wish to request a 24-month NCE to complete previously approved activities for the award listed above. Please mark the reason(s) funds remain on the award you are requesting a NCE on:
- ☐ Delay in securing spend authority from state, county, city, or territorial legislature.
 - ☐ Significant delay in hiring one or more positions and/or significant attrition resulting in cost savings from personnel.
 - ☐ Significant delay in executing contract(s) critical to the success of your approved activities.
 - ☐ Other (please specify):
- ☐ Yes, some of this funding will be used to purchase COVID-19 vaccines for adults.
- ☒ Yes, under a 24-mo NCE, approved activities will be successfully completed.
- ☒ Yes, confirming that activities, workplans, and budgets align with the previously approved activities for the 24-mo NCE period.
- ☒ Yes, understand that progress will be monitored on a quarterly basis, including financial reporting.
- ☒ Other additional context: Request for \$22,611,327.90 per carry-forward request.

8.

Award Title	1901 Immunization and Vaccines for Children (COVID 4 Ukraine)
PMS Document Number	20NH23IP922625UKR
Budget Year (BY)	2022 (BY 4)
Award Total	\$142,095
Unobligated	\$142,095

☐ Yes, I wish to request a 24-month NCE to complete previously approved activities for the award listed above.
Please mark the reason(s) funds remain on the award you are requesting a NCE on:

- ☐ Delay in securing spend authority from state, county, city, or territorial legislature.
- ☐ Significant delay in hiring one or more positions and/or significant attrition resulting in cost savings from personnel.
- ☐ Significant delay in executing contract(s) critical to the success of your approved activities.
- ☐ Other (please specify):

- ☐ Yes, some of this funding will be used to purchase COVID-19 vaccines for adults.
- ☐ Yes, under a 24-mo NCE, approved activities will be successfully completed.
- ☐ Yes, confirming that activities, workplans, and budgets align with the previously approved activities for the 24-mo NCE period.
- ☐ Yes, understand that progress will be monitored on a quarterly basis, including financial reporting.
- ☐ Other additional context:

Signature of Authorizing Official

Kara M. Connolly

Date 2/24/25

Jonathan Fanning

Date 2/24/25

Wet signature to follow